

WEST Search History

DATE: Monday, October 28, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
L2	Sanders-Mitchell-CS.in.	1	L2
L1	Sanders-Mitchel-CS.in.	0	L1

END OF SEARCH HISTORY

Inventor Names Search.

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: US 20020142384 A1

L2: Entry 1 of 1

File: PGPB

Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142384

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020142384 A1

TITLE: Method and device for improving protein stability and solubility

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Sanders, Mitchell C.</u>	Leicester	MA	US	

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 530/350, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

[Generate Collection](#)[Print](#)

Term	Documents
SANDERS-MITCHELL-C\$	0
SANDERS-MITCHELL-C.DWPI,EPAB,USPT,PGPB.	1
SANDERS-MITCHELL-C\$.IN..USPT,PGPB,EPAB,DWPI,TDBD.	1
(SANDERS-MITCHELL-C\$.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	1

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

=> index patents bioscience meetings business

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.06	1.48

FULL ESTIMATED COST

INDEX 'CAOLD, CAPLUS, CASREACT, CROPU, DGENE, DPCI, ENCOMPPAT, ENCOMPPAT2, EUROPATFULL, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE, PATOSEP, PATOSWO, PCTFULL, PIRA, RAPRA, SYNTHLINE, TULSA, TULSA2, USPATFULL, USPAT2, WPIDS, WPINDEX, ADISALERTS, ...'

ENTERED AT 19:00:24 ON 28 OCT 2002

103 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (alpha (w) crystallin) and (HIS-tagged or histidine or NTA)

21 FILE CAPLUS
5 FILE EUROPATFULL
1 FILE IFIPAT

18 FILES SEARCHED...

24 FILE PCTFULL
26 FILE USPATFULL
1 FILE WPIDS
1 FILE WPINDEX
1 FILE AGRICOLA
1 FILE BIOBUSINESS
17 FILE BIOSIS

37 FILES SEARCHED...

1 FILE BIOTECHABS
1 FILE BIOTECHDS
3 FILE BIOTECHNO
1 FILE CABA
1 FILE DDFU
2 FILE DRUGU
11 FILE EMBASE

57 FILES SEARCHED...

5 FILE ESBIODBASE
4 FILE GENBANK
1 FILE JICST-EPLUS
1 FILE LIFESCI
12 FILE MEDLINE
2 FILE PASCAL

79 FILES SEARCHED...

16 FILE SCISEARCH
11 FILE TOXCENTER

25 FILES HAVE ONE OR MORE ANSWERS, 103 FILES SEARCHED IN STNINDEX

L1 QUE (ALPHA (W) CRYSTALLIN) AND (HIS-TAGGED OR HISTIDINE OR NTA)

=> file hits

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.65	4.13

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 19:03:25 ON 28 OCT 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 19:03:25 ON 28 OCT 2002

COPYRIGHT (C) 2002 Univentio

FILE 'CAPLUS' ENTERED AT 19:03:25 ON 28 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'MEDLINE' ENTERED AT 19:03:25 ON 28 OCT 2002

FILE 'EMBASE' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 ACS

FILE 'EUROPATFULL' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'ESBIOBASE' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'GENBANK' ENTERED AT 19:03:25 ON 28 OCT 2002

FILE 'BIOTECHNO' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DRUGU' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'PASCAL' ENTERED AT 19:03:25 ON 28 OCT 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'IFIPAT' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'WPIDS' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'AGRICOLA' ENTERED AT 19:03:25 ON 28 OCT 2002

FILE 'BIOBUSINESS' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CABA' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'JICST-EPLUS' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'LIFESCI' ENTERED AT 19:03:25 ON 28 OCT 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

```
=> s l1
L2      26 FILE USPATFULL
L3      24 FILE PCTFULL
L4      21 FILE CAPLUS
L5      17 FILE BIOSIS
L6      16 FILE SCISEARCH
L7      12 FILE MEDLINE
L8      11 FILE EMBASE
L9      11 FILE TOXCENTER
L10     5 FILE EUROPATFULL
L11     5 FILE ESBIODBASE
L12     4 FILE GENBANK
L13     3 FILE BIOTECHNO
L14     2 FILE DRUGU
L15     2 FILE PASCAL
L16     1 FILE IFIPAT
L17     1 FILE WPIDS
L18     1 FILE AGRICOLA
L19     1 FILE BIOBUSINESS
L20     1 FILE BIOTECHDS
L21     1 FILE CABA
L22     1 FILE JICST-EPLUS
L23     1 FILE LIFESCI
```

TOTAL FOR ALL FILES

```
L24      167 L1
```

```
=> s l24 and (purifying or purification or purify) vector
MISSING OPERATOR PURIFY) VECTOR
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
```

```
=> s l24 and (purifying or purification or purify)and vector
```

```
L25     21 FILE USPATFULL
L26     23 FILE PCTFULL
L27      1 FILE CAPLUS
L28      0 FILE BIOSIS
L29      0 FILE SCISEARCH
L30      0 FILE MEDLINE
L31      0 FILE EMBASE
L32      0 FILE TOXCENTER
L33      3 FILE EUROPATFULL
L34      0 FILE ESBIODBASE
L35      0 FILE GENBANK
L36      0 FILE BIOTECHNO
L37      0 FILE DRUGU
L38      0 FILE PASCAL
L39      1 FILE IFIPAT
L40      1 FILE WPIDS
L41      0 FILE AGRICOLA
L42      0 FILE BIOBUSINESS
L43      1 FILE BIOTECHDS
L44      0 FILE CABA
L45      0 FILE JICST-EPLUS
L46      0 FILE LIFESCI
```

TOTAL FOR ALL FILES

```
L47      51 L24 AND (PURIFYING OR PURIFICATION OR PURIFY) AND VECTOR
```

```
=> dup rem l47
```

DUPLICATE IS NOT AVAILABLE IN 'GENBANK'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L47

```
L48      48 DUP REM L47 (3 DUPLICATES REMOVED)
```

=> d 148 1-48 ibib abs

L48 ANSWER 1 OF 48 USPATFULL DUPLICATE 1
ACCESSION NUMBER: 2002:258814 USPATFULL
TITLE: Method and device for improving protein stability and
solubility
INVENTOR(S): Sanders, Mitchell C., Leicester, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142384	A1	20021003
APPLICATION INFO.:	US 2001-848780	A1	20010503 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201407P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or **alpha crystallin** type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the mutiple cloning site of the **PROTECT Vector** System just downstream of the p26 or **alpha crystallin** type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac I.sub.q). The soluble recombinant protein is purified using a fusion tag.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 2 OF 48 USPATFULL
ACCESSION NUMBER: 2002:280000 USPATFULL
TITLE: Hepatitis B virus treatment
INVENTOR(S): Mizzen, Lee A., Victoria, CANADA
Siegel, Marvin, Blue Bell, PA, UNITED STATES
Liu, Hongwei, Victoria, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002155434	A1	20021024
APPLICATION INFO.:	US 2002-68059	A1	20020205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266733P	20010205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LEE CREWS, PH.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	1452	

AB The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions

comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.

L48 ANSWER 3 OF 48 USPATFULL

ACCESSION NUMBER: 2002:221323 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna L., Mount Airy, MD, UNITED STATES
Porter, Mark W., Germantown, MD, UNITED STATES
Johnson, Kory R., Bethesda, MD, UNITED STATES
Castle, Arthur L., Washington, DC, UNITED STATES
Elashoff, Michael R., Germantown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119462	A1	20020829
APPLICATION INFO.:	US 2001-917800	A1	20010731 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-222040P	20000731 (60)
	US 2000-244880P	20001102 (60)
	US 2001-290029P	20010511 (60)
	US 2001-290645P	20010515 (60)
	US 2001-292336P	20010522 (60)
	US 2001-295798P	20010606 (60)
	US 2001-297457P	20010613 (60)
	US 2001-298884P	20010619 (60)
	US 2001-303459P	20010709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE
NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 9801

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 4 OF 48 USPATFULL

ACCESSION NUMBER: 2002:205879 USPATFULL
TITLE: Human papilloma virus treatment
INVENTOR(S): Neefe, John R., Devon, PA, UNITED STATES
Goldstone, Stephen E., New York, NY, UNITED STATES
Winnett, Mark T., Phoenixville, PA, UNITED STATES
Siegel, Marvin, Blue Bell, PA, UNITED STATES
Boux, Leslie J., Victoria, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110566	A1	20020815
APPLICATION INFO.:	US 2001-891823	A1	20010626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214202P	20000626 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: LEE CREWS, PH. D., Fish & Richardson P.C., 225 Franklin
Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 1257

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 5 OF 48 USPATFULL

ACCESSION NUMBER: 2002:199080 USPATFULL
TITLE: Regulation of biological events using novel compounds
INVENTOR(S): Clackson, Timothy P., Arlington, MA, UNITED STATES
Gilman, Michael Z., Newton, MA, UNITED STATES
Holt, Dennis A., Schwenksville, PA, UNITED STATES
Keenan, Terence P., Cambridge, MA, UNITED STATES
Rozamus, Leonard, Bedford, MA, UNITED STATES
Yang, Wu, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107189	A1	20020808
APPLICATION INFO.:	US 2001-781804	A1	20010212 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-12097, filed on 22 Jan 1998, GRANTED, Pat. No. US 6187757 Continuation-in-part of Ser. No. US 1997-791044, filed on 28 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1995-481941, filed on 7 Jun 1995, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1996-US9948	19960607
	US 1996-15502P	19960209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David L. Bernstein, ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	5858	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 6 OF 48 USPATFULL

ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102604	A1	20020801
APPLICATION INFO.:	US 2000-731872	A1	20001207 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John Lucas, Ph.D., J.D., Genset Corporation, 10665 Sorento Valley Road, San Diego, CA, 92121-1609	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	28061	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression **vectors**. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 7 OF 48 USPATFULL

ACCESSION NUMBER: 2002:178550 USPATFULL
 TITLE: Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
 INVENTOR(S): Andersen, Peter, Bronshoj, DENMARK
 Nielsen, Rikke, Frederiksberg C, DENMARK
 Oettinger, Thomas, Hellerup, DENMARK
 Rasmussen, Peter Birk, Kobenhaven O, DENMARK
 Rosenkrands, Ida, Kobenhaven O, DENMARK
 Weldingh, Karin, Kobenhaven N, DENMARK
 Florio, Walter, Frederiksberg C, DENMARK
 PATENT ASSIGNEE(S): STATENS SERUM INSTITUT (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094336	A1	20020718
APPLICATION INFO.:	US 2001-791171	A1	20010220 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-50739, filed on 30 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1997-376	19970402
	DK 1997-1277	19971110
	US 1997-44624P	19970418 (60)
	US 1998-70488P	19980105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FROMMER LAWRENCE & HAUG LLP, 745 FIFTH AVENUE, NEW YORK, NY, 10151	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	6134	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based on the identification and

characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 8 OF 48 USPATFULL

ACCESSION NUMBER: 2002:157089 USPATFULL
TITLE: Retinoid pathway assays, and compositions therefrom
INVENTOR(S): Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
Richards, Burt Timothy, Midway, UT, UNITED STATES
Karpilow, Jon, Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081688	A1	20020627
APPLICATION INFO.:	US 2001-990747	A1	20011116 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-812994, filed on 4 Mar 1997, GRANTED, Pat. No. US 5955275		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249468P	20001117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Joseph A. Williams, Jr., MARSHALL, GERSTEIN, MURRAY & BORUN, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL, 60606-6402	
NUMBER OF CLAIMS:	110	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	33 Drawing Page(s)	
LINE COUNT:	3714	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for assaying a cellular pathway, and more particularly a retinoic acid-related pathway, are disclosed. The assays of the invention utilize particular host cells with desired retinoic acid pathway elements, and results in the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 9 OF 48 USPATFULL

ACCESSION NUMBER: 2002:8197 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., Lexington, MA, UNITED STATES
Nyanguile, Origene, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004195	A1	20020110
APPLICATION INFO.:	US 2000-751309	A1	20001229 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-208057, filed on 9 Dec 1998, GRANTED, Pat. No. US 6183965 Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997, GRANTED, Pat. No. US 6153383		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE
SQUARE, BOSTON, MA, 02109
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 3196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 10 OF 48 USPATFULL

ACCESSION NUMBER: 2002:254057 USPATFULL
TITLE: Compounds and methods for diagnosis of tuberculosis
INVENTOR(S): Reed, Steven G., Bellevue, WA, United States
Skeiky, Yasir A. W., Seattle, WA, United States
Dillon, Davin C., Redmond, WA, United States
Campos-Neto, Antonio, Bainbridge Island, WA, United States
Houghton, Raymond, Bothell, WA, United States
Vedvick, Thomas S., Federal Way, WA, United States
Twardzik, Daniel R., Bainbridge Island, WA, United States
Lodes, Michael J., Seattle, WA, United States
Hendrickson, Ronald C., Seattle, WA, United States
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458366	B1	20021001
APPLICATION INFO.:	US 1998-72596		19980505 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-24753, filed on 18 Feb 1998, now abandoned Continuation-in-part of Ser. No. US 1997-942341, filed on 1 Oct 1997, now abandoned Continuation-in-part of Ser. No. US 1997-818111, filed on 13 Mar 1997 Continuation-in-part of Ser. No. US 1996-729622, filed on 11 Oct 1996, now abandoned Continuation-in-part of Ser. No. US 1996-680574, filed on 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US 1996-658800, filed on 5 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1996-620280, filed on 22 Mar 1996, now abandoned Continuation-in-part of Ser. No. US 1995-532136, filed on 22 Sep 1995, now abandoned Continuation of Ser. No. US 1995-523435, filed on 1 Sep 1995, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1996-US14675	19960830
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Swartz, Rodney P.	
LEGAL REPRESENTATIVE:	Townsend & Townsend & Crew, LLP	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 19 Drawing Page(s)	

LINE COUNT: 8789

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 11 OF 48 USPATFULL

ACCESSION NUMBER: 2002:95352 USPATFULL
TITLE: Composition and method for the prevention and treatment of oxidative damage in ocular tissues
INVENTOR(S): Lou, Marjorie F., Lincoln, NE, United States
Raghavachari, Nalini, Lincoln, NE, United States
Qiao, Fengyu, Lincoln, NE, United States
PATENT ASSIGNEE(S): Board of Regents University of Nebraska-Lincoln, Lincoln, NE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6379664	B1	20020430
APPLICATION INFO.:	US 1998-162564		19980929 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Prouty, Rebecca E.		
ASSISTANT EXAMINER:	Hutson, Richard		
LEGAL REPRESENTATIVE:	Suiter & Associates PC, Rand, Scott C., Breen, III, William J.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1710		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Thioltransferase and derivatives thereof are provided. Methods of treating or preventing cataract formation comprising administering thioltransferase or a derivative thereof are also provided. Thioltransferase or derivatives thereof are also useful for treating or preventing diseases resulting from or associated with oxidative stress. Human lens thioltransferase and a DNA sequence encoding the same are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 12 OF 48 USPATFULL

ACCESSION NUMBER: 2002:39663 USPATFULL
TITLE: Compositions and methods for the prevention and treatment of M. tuberculosis infection
INVENTOR(S): Reed, Steven G., Bellevue, WA, United States
Skeiky, Yasir A. W., Seattle, WA, United States
Dillon, Davin C., Redmond, WA, United States
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350456	B1	20020226
APPLICATION INFO.:	US 1998-56556		19980407 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998, now abandoned Continuation-in-part of Ser. No. US 1997-942578, filed on 1 Oct 1997, now		

abandoned Continuation-in-part of Ser. No. US
1997-818112, filed on 13 Mar 1997

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Swartz, Rodney P
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 6417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for treatment and vaccination against tuberculosis are disclosed. In one aspect the compositions provided include at least two polypeptides that contain an immunogenic portion of a M. tuberculosis antigen or at least two DNA molecules encoding such polypeptides. In a second aspect, the compositions provided include a fusion protein comprising at least two polypeptides that contain an immunogenic portion of a M. tuberculosis antigen. Such compositions may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 13 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002081731 PCTFULL ED 20021028 EW 200242
TITLE (ENGLISH): NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
TITLE (FRENCH): NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES
INVENTOR(S): TANG, Tom, Y.; LIU, Chenghua; ZHOU, Ping; ASUNDI, Vinod; ZHANG, Jie; ZHAO, Qing, A.; REN, Feiyan; XUE, Aidong, J.; YANG, Yonghong; WEHRMAN, Tom; WANG, Jian-Rui; WANG, Dunrui; DRMANAC, Radoje, T.
PATENT ASSIGNEE(S): HYSEQ, INC., for all designates States except US; GOODRICH, Ryle, W., for US only; TANG, Tom, Y., for US only; LIU, Chenghua, for US only; ZHOU, Ping, for US only; ASUNDI, Vinod, for US only; ZHANG, Jie, for US only; ZHAO, Qing, A., for US only; REN, Feiyan, for US only; XUE, Aidong, J., for US only; YANG, Yonghong, for US only; WEHRMAN, Tom, for US only; WANG, Jian-Rui, for US only; WANG, Dunrui, for US only; DRMANAC, Radoje, T., for US only
AGENT: HSI, Petrina, S.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2002081731	A2	20021017
---------------	----	----------

DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
-------------------	--

APPLICATION INFO.:	WO 2002-US1222	A	20020129
PRIORITY INFO.:	US 2001-09/774,528		20010130

ABEN The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

ABFR La presente invention concerne de nouveaux acides nucleiques, de nouvelles sequences polypeptidiques codees par ces acides nucleiques, et leurs utilisations.

L48 ANSWER 14 OF 48 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2002067982 PCTFULL ED 20020916 EW 200236
 TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR THERAPEUTIC INTERVENTION
 IN INFECTIOUS DISEASE
 TITLE (FRENCH): METHODES ET COMPOSITIONS D'INTERVENTION THERAPEUTIQUE
 DANS LE CADRE D'UNE MALADIE INFECTIEUSE
 INVENTOR(S): YOUNG, Douglas, Brownlie; STEWART, Graham, Roger;
 O'GAORA, Peadar, Caoimhin Eoin
 PATENT ASSIGNEE(S): SEQUELLA, INC., for all designates States except US;
 YOUNG, Douglas, Brownlie; STEWART, Graham, Roger;
 O'GAORA, Peadar, Caoimhin Eoin
 AGENT: PRATT, John
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002067982	A2	20020906
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US5038	A	20020220
PRIORITY INFO.:	US 2001-60/269,801		20010220
	US 2001-60/294,170		20010529

ABEN Methods and compositions for the treatment and prevention of infectious diseases are provided. In particular, efficient vaccines comprising genetically modified pathogens are provided. The vaccines generally comprise mycobacterial mutants having modified protein production capabilities. In one embodiment, the mutants overexpress heat shock protein. In a specific embodiment, the mycobacterial mutant overexpresses heat shock proteins 60 and/or 70. Also provided are modified BCG vaccines capable of overexpressing heat shock proteins 60 and/or 70.

ABFR Cette invention concerne des methodes et des compositions destinees au traitement et a la prevention de maladies infectieuses. Notamment, l'invention a trait a des vaccins efficaces renfermant des agents pathogenes genetiquement modifies. Les vaccins contiennent generalement des mutants de mycobacteriose presentant des capacites de production de proteines modifiees. Selon un mode de realisation, les mutants surexpriment la proteine du stress. Selon un mode de realisation specifique, le mutant de mycobacteriose surexprime les proteines du stress 60 et/ou 70. Ladite invention concerne aussi des vaccins du BCG modifies capables de surexprimer les proteines du stress 60 et/ou 70.

L48 ANSWER 15 OF 48 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2002062959 PCTFULL ED 20020827 EW 200233
 TITLE (ENGLISH): HEPATITIS B VIRUS TREATMENT
 TITLE (FRENCH): TRAITEMENT DU VIRUS DE L'HEPATITE B
 INVENTOR(S): MIZZEN, Lee; LIU, Hongwei; SIEGEL, Marvin
 PATENT ASSIGNEE(S): STRESSGEN BIOTECHNOLOGIES CORP., for all designates
 States except US; MIZZEN, Lee, for US only; LIU,
 Hongwei, for US only; SIEGEL, Marvin, for US only
 AGENT: FRASER, Janis, K.
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

	WO 2002062959 A2 20020815
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2002-US3460 A 20020205
PRIORITY INFO.:	US 2001-60/266,733 20010205
ABEN	The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (<i>e.g.</i>, a fragment) or derivative thereof, and an HBV antigen.
ABFR	L'invention concerne des compositions contenant un antigene du virus de l'hepatite B (HBV) utilisees pour traiter ou prevenir une infection induite par le HBV. Le contenu des compositions peut varier, et ces compositions comprennent une proteine de stress, ou une partie (par exemple, un fragment) ou un derive de celle-ci, et un antigene contre le HBV.
L48	ANSWER 16 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER:	2002054073 PCTFULL ED 20020723 EW 200228
TITLE (ENGLISH):	LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE
TITLE (FRENCH):	MODELE DE TUBERCULOSE HUMAINE LATENTE, ANTIGENES DIAGNOSTIQUES ET METHODES D'UTILISATION ASSOCIEES
INVENTOR(S):	QUINN, Frederick, D.; BIRKNESS, Kristin, A.; DESLAURIERS, Manon; KING, Peter; BEALL, David, S.
PATENT ASSIGNEE(S):	THE GOVERNEMENT OF THE UNITED STATES, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, for all designates States except US; QUINN, Frederick, D., for US only; BIRKNESS, Kristin, A., for US only; DESLAURIERS, Manon, for US only; KING, Peter, for US only; BEALL, David, S., for US only
AGENT:	HARDING, Tanya, M.
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	
	NUMBER KIND DATE

	WO 2002054073 A2 20020711
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2002-US309 A 20020107
PRIORITY INFO.:	US 2001-60/260,348 20010108
	US 2001-60/311,235 20010809
ABEN	Provided herein is an <i>in vitro</i> granuloma model and methods of its use. Methods of detecting and/or diagnosing latent tuberculosis in a subject are also provided, as are latency-specific antigens (and antibodies thereto), such as α-crystallin, and methods of identifying and using such molecules. Also provided are immunostimulatory compositions, for instance for use in eliciting an immune response in a subject, such as an immune response to a latent

tuberculosis infection. Kits for carrying out the provided methods are also described.

ABFR L'invention concerne un modele de granuloma <i>in vitro</i> et ses methodes d'utilisation. L'invention concerne egalement des methodes de detection et/ou de diagnostic de la tuberculose latente chez un sujet, des antigenes specifiques de latence (et les anticorps de ceux-ci), par exemple de type α -cristallin, et des methodes d'identification et d'utilisation de ces molecules. Par ailleurs, l'invention concerne des composition immunostimulantes, utilisees notamment pour provoquer une reponse immunitaire chez un sujet, par exemple une reponse immunitaire vis a vis d'une infection tuberculeuse latente. Enfin, l'invention concerne des kits d'application de ces methodes.

L48 ANSWER 17 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002040719 PCTFULL ED 20020610 EW 200221
TITLE (ENGLISH): RETINOID PATHWAY ASSAYS, AND COMPOSITIONS THEREFROM
TITLE (FRENCH): DOSAGES DE VOIES DU RETINOIDE, ET COMPOSITIONS
CORRESPONDANTES
INVENTOR(S): KAMB, Carl, Alexander; RICHARDS, Burt, Timothy;
KARPILOW, Jon
PATENT ASSIGNEE(S): DELTAGEN PROTEOMICS, INC., for all designates States
except US; KAMB, Carl, Alexander, for US only;
RICHARDS, Burt, Timothy, for US only; KARPILOW, Jon,
for US only
AGENT: WILLIAMS, Joseph, A., Jr.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002040719	A2	20020523
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US44039	A	20011117
PRIORITY INFO.:	US 2000-60/249,468		20001117

ABEN Methods for assaying a cellular pathway, and more particularly a retinoic acid-related pathway, are disclosed. The assays of the invention utilize particular host cells with desired retinoic acid pathway elements, and results in the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

ABFR L'invention concerne des methodes de dosage d'une voie cellulaire, et plus specifiquement, d'une voie afferente a l'acide retinoique. Les dosages de cette invention utilisent des cellules hotes specifiques avec des elements de voies d'acide retinoique, ainsi que des resultats d'identification des sonde phenotypiques actives biologiquement et de fragments et cibles cellulaires, des variants et des substances mimetiques correspondantes.

L48 ANSWER 18 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002010433 PCTFULL ED 20020814
TITLE (ENGLISH): A DEVICE FOR DETECTING BACTERIAL CONTAMINATION AND
METHOD OF USE
TITLE (FRENCH): DISPOSITIF DE DETECTION DE CONTAMINATION BACTERIENNE ET
PROCEDE D'UTILISATION

INVENTOR(S): SANDERS, Mitchell, C.
PATENT ASSIGNEE(S): EXPRESSIVE CONSTRUCTS, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

DESIGNATED STATES WO 2002010433 A2 20020207
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US14613 A 20010503
PRIORITY INFO.: US 2000-60/201,405 20000503

ABEN A device and method for detecting the presence or absence of a prokaryotic microorganism are provided, comprising the steps of identifying a protein, such as a microbial-specific protease that characterizes the presence of a specific prokaryotic microbe and thereby provides a marker for that microbe; detecting the protease that is a marker for the presence of a specific prokaryotic microbe by cleaving a substance when the protease is present; and signaling the presence of that protease when cleavage has occurred. More specifically, the method comprises identifying at least one outer membrane protein or a secreted protein that is unique to a particular microbial pathogen such as for example *Listeria monocytogenes* and that is substrate specific.

ABFR L'invention concerne un dispositif et un procede de detection de la presence ou de l'absence de micro-organisme procaryote, le procede consistant a identifier une proteine, telle qu'une protease microbienne qui caracterise la presence d'un microbe procaryote specifique et fournit ainsi un marqueur pour ce microbe, a detecter la protease marqueur revelant la presence d'un microbe procaryote specifique par clivage d'une substance lorsque la protease est presente, et a signaler la presence de cette protease lorsque le clivage est realise. Le procede consiste, plus specifiquement, a identifier au moins une proteine de membrane exterieure ou une proteine secretee, unique d'un pathogene microbien particulier tel que, par exemple, *Listeria monocytogenes* et qui presente une specificite de substrat.

L48 ANSWER 19 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002000242 PCTFULL ED 20020814
TITLE (ENGLISH): HUMAN PAPILLOMA VIRUS TREATMENT
TITLE (FRENCH): TRAITEMENT DES INFECTIONS PAR LE PAPILLOMAVIRUS
INVENTOR(S): NEEFE, John; GOLDSTONE, Stephen; WINNETT, Mark; SIEGEL, Marvin
PATENT ASSIGNEE(S): STESSGEN BIOTECHNOLOGIES CORPORATION; NEEFE, John; GOLDSTONE, Stephen; WINNETT, Mark; SIEGEL, Marvin
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

DESIGNATED STATES WO 2002000242 A2 20020103
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US20240 A 20010626
PRIORITY INFO.: US 2000-60/214,202 20000626

ABEN Disclosed is a method of treating a wart in a subject by administering

to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

ABFR L'invention se rapporte a une methode de traitement d'une verrue qui consiste a administrer au sujet presentant ladite verrue une composition contenant (1) une proteine de stress ou un fragment immunostimulateur d'une telle proteine, et (2) une proteine d'un papillomavirus ou un fragment antigenique dudit virus. L'invention se rapporte egalement a une methode de traitement d'une infection par papillomavirus chez un sujet infecte ou susceptible d'etre infecte par un papillomavirus d'un premier type, ledit procede consistant a administrer au sujet en question une composition contenant une proteine de stress ou un fragment antigenique d'une telle proteine et (2) une proteine d'un papillomavirus d'un second type ou un fragment antigenique d'une telle proteine, lesdits premier et second type de papillomavirus etant differents.

L48 ANSWER 20 OF 48 PCTFULL COPYRIGHT 2002 UniventioDUPLICATE 2
 ACCESSION NUMBER: 2001083804 PCTFULL ED 20020826
 TITLE (ENGLISH): A METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND SOLUBILITY
 TITLE (FRENCH): METHODE ET DISPOSITIF POUR AMELIORER LA STABILITE ET LA SOLUBILITE DE PROTEINES
 INVENTOR(S): SANDERS, Mitchell, C.
 PATENT ASSIGNEE(S): EXPRESSIVE CONSTRUCTS, INC.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001083804	A2	20011108
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US14692	A	20010503
PRIORITY INFO.:	US 2000-60/201,407		20000503

ABEN A method for expressing proteins as a fusion chimera with a domain of p26 or **alpha crystallin** type proteins to improve the protein stability and solubility when over expressed in bacteria such as *E. Coli* is provided. Genes of interest are cloned into the multiple cloning site of the **PROTECT Vector** System just downstream of the p26 or **alpha crystallin** type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of **lmMIPTG** that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.

ABFR L'invention concerne une methode servant a exprimer des proteines en tant que chimere de fusion presentant un domaine proteique de type p26 ou **alpha-crystallin**, destinee a ameliorer la stabilite et la solubilite des proteines lorsqu'elles sont exprimees excessivement dans des bacteries telles que *E. Coli*. Des genes d'interet sont clones dans le site de clonage multiple du systeme vectorette **PROTECT** juste en aval de la proteine de type p26 ou **alpha-crystallin** et d'un site de clivage de thrombine. L'expression proteique est effectuee par un puissant promoteur bacterien (TAC). Cette expression est induite par l'addition de **lmMIPTG** qui

surmonte la repression de lac (lac Iq). La proteine recombinante soluble est purifiee au moyen d'un fragment de fusion.

L48 ANSWER 21 OF 48 USPATFULL

ACCESSION NUMBER: 2001:220852 USPATFULL
TITLE: Chimeric DNA-binding proteins
INVENTOR(S): Pomerantz, Joel L., Cambridge, MA, United States
Sharp, Phillip A., Newton, MA, United States
Pabo, Carl O., Newton, MA, United States
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326166	B1	20011204
	WO 9620951		19960711
APPLICATION INFO.:	US 1998-973131		19980316 (8)
	WO 1995-US16982		19951229
			19980316 PCT 371 date
			19980316 PCT 102(e) date

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Martinell, James
LEGAL REPRESENTATIVE: Vincent, Matthew P.Ropes & Gray, LLP
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2890

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 22 OF 48 USPATFULL

ACCESSION NUMBER: 2001:185087 USPATFULL
TITLE: Heterologous transcription factors
INVENTOR(S): Gilman, Michael Z., Newton, MA, United States
Natesan, Sridaran, Chestnut Hill, MA, United States
PATENT ASSIGNEE(S): ARIAD Gene Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6306649	B1	20011023
APPLICATION INFO.:	US 1996-672213		19960627 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-553P	19950627 (60)
	US 1995-19614P	19951229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Martin, Jill D.	
LEGAL REPRESENTATIVE:	Berstein, David L.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	2484	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials

useful for practicing the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 23 OF 48 USPATFULL

ACCESSION NUMBER: 2001:22203 USPATFULL
TITLE: Regulation of biological events using novel compounds
INVENTOR(S): Clackson, Timothy P., Cambridge, MA, United States
Gilman, Michael Z., Newton, MA, United States
Holt, Dennis A., Royersford, PA, United States
Keenan, Terence P., Cambridge, MA, United States
Rozamus, Leonard, Bedford, MA, United States
Yang, Wu, Plainsboro, NJ, United States
PATENT ASSIGNEE(S): ARIAD Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6187757	B1	20010213
APPLICATION INFO.:	US 1998-12097		19980122 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-791044, filed on 28 Jan 1997 Continuation-in-part of Ser. No. US 1995-481941, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. WO 1996-US9948, filed on 7 Jun 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Berstein, David L.		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	5678		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 24 OF 48 USPATFULL

ACCESSION NUMBER: 2001:18213 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., Lexington, MA, United States
Nyanguile, Origene, Gaithersburg, MD, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183965	B1	20010206
APPLICATION INFO.:	US 1998-208057		19981209 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot, LLP, Clauss, Isabelle M., Vincent, Matthew P.		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	3213		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected

ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 25 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001079274 PCTFULL ED 20020826
TITLE (ENGLISH): M. TUBERCULOSIS ANTIGENS
TITLE (FRENCH): ANTIGENES DE LA TUBERCULOSE
INVENTOR(S): AGGER, Else, Marie; ANDERSEN, Peter; OKKELS, Li, Mei, Meng; WELDINGH, Karin
PATENT ASSIGNEE(S): STATENS SERUM INSTITUT; AGGER, Else, Marie; ANDERSEN, Peter; OKKELS, Li, Mei, Meng; WELDINGH, Karin
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001079274	A2	20011025
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW		
	GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-DK276	A	20010419
PRIORITY INFO.:	DK 2000-PA 2000 00666		20000419
	DK 2001-PA 2001 00283		20010221
ABEN	The present invention is based on the identification and characterization of a number of novel <i>M. tuberculosis</i> derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.		
ABFR	La presente invention concerne l'identification et la caracterisation de plusieurs nouvelles proteines et nouveaux fragments de proteines derivees de <i>M. tuberculosis</i>. L'invention se rapporte aux polypeptides et aux fragments immunologiquement actifs de ceux-ci, aux genes les codant, a des compositions immunologiques telles que des vaccins et a des reactifs pour tests cutanes contenant les polypeptides de l'invention.		

L48 ANSWER 26 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001057190 PCTFULL ED 20020827
TITLE (ENGLISH): NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
TITLE (FRENCH): ACIDES NUCLEIQUES ET POLYPEPTIDES
INVENTOR(S): TANG, Y., Tom; LIU, Chenghua; DRMANAC, Radoje, T.; ASUNDI, Vinod; ZHOU, Ping; XU, Chongjun; CAO, Yicheng; MA, Yunqing; ZHAO, Qing, A.; WANG, Dunrui; WANG, Jian-Rui; ZHANG, Jie; REN, Feiyan; CHEN, Rui-hong; WANG, Zhi, Wei; XUE, Aidong, J.; YANG, Yonghong; WEJHRMAN, Tom; GOODRICH, Ryle
PATENT ASSIGNEE(S): HYSEQ, INC.; TANG, Y., Tom; LIU, Chenghua; DRMANAC, Radoje, T.; ASUNDI, Vinod; ZHOU, Ping; XU, Chongjun; CAO, Yicheng; MA, Yunqing; ZHAO, Qing, A.; WANG, Dunrui; WANG, Jian-Rui; ZHANG, Jie; REN, Feiyan; CHEN, Rui-hong; WANG, Zhi, Wei; XUE, Aidong, J.; YANG, Yonghong; WEJHRMAN, Tom; GOODRICH, Ryle
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001057190	A2	20010809
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US4098	A	20010205
PRIORITY INFO.:	US 2000-09/496,914		20000203
	US 2000-09/560,875		20000427
	US 2000-09/598,075		20000620
	US 2000-09/620,325		20000719
	US 2000-09/654,936		20000901
	US 2000-09/663,561		20000915
	US 2000-09/693,325		20001020
	US 2000-09/728,422		20001130
ABEN	The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.		
ABFR	L'invention concerne des acides nucleiques, des sequences polypeptidiques codees par ces acides nucleiques et leurs utilisations correspondantes.		
L48	ANSWER 27 OF 48 PCTFULL COPYRIGHT 2002 Univentio		
ACCESSION NUMBER:	2001053312 PCTFULL ED 20020827		
TITLE (ENGLISH):	NOVEL NUCLEIC ACIDS AND POLYPEPTIDES		
TITLE (FRENCH):	NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES		
INVENTOR(S):	TANG, Y., Tom; LIU, Chenghua; ASUNDI, Vinod; CHEN, Rui-hong; MA, Yunqing; QIAN, Xiaohong, B.; REN, Feiyan; WANG, Dunrui; WANG, Jian-Rui; WANG, Zhiwei; WEHRMAN, Tom; XU, Chongjun; XUE, Aidong, J.; YANG, Yonghong; ZHANG, Jie; ZHAO, Qing, A.; ZHOU, Ping; GOODRICH, Ryle; DRMANAC, Radoje, T.		
PATENT ASSIGNEE(S):	HYSEQ, INC.; TANG, Y., Tom; LIU, Chenghua; ASUNDI, Vinod; CHEN, Rui-hong; MA, Yunqing; QIAN, Xiaohong, B.; REN, Feiyan; WANG, Dunrui; WANG, Jian-Rui; WANG, Zhiwei; WEHRMAN, Tom; XU, Chongjun; XUE, Aidong, J.; YANG, Yonghong; ZHANG, Jie; ZHAO, Qing, A.; ZHOU, Ping; GOODRICH, Ryle; DRMANAC, Radoje, T.		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:			
	NUMBER	KIND	DATE
	WO 2001053312	A1	20010726
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US34263	A	20001226
PRIORITY INFO.:	US 1999-09/471,275		19991223
	US 2000-09/488,725		20000121
	US 2000-09/552,317		20000425
	US 2000-09/598,042		20000709
	US 2000-09/620,312		20000719
	US 2000-09/653,450		20000803
	US 2000-09/662,191		20000914
	US 2000-09/693,036		20001019
	US 2000-09/727,344		20001129

ABEN The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.
ABFR La presente invention se rapporte a de nouveaux acides nucleiques et a de nouvelles sequences polypeptidiques codees par lesdits acides nucleiques, ainsi qu'a leur utilisation.

L48 ANSWER 28 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001014387 PCTFULL ED 20020828
TITLE (ENGLISH): 28-EPIRAPALOGS
TITLE (FRENCH): ANALOGUES D'EPIRAPAMYCINE-28
INVENTOR(S): YANG, Wu; DIGITS, Cheryl, A.; ROZAMUS, Leonard; HOLT, Dennis, A.
PATENT ASSIGNEE(S): ARIAD GENE THERAPEUTICS, INC.; YANG, Wu; DIGITS, Cheryl, A.; ROZAMUS, Leonard; HOLT, Dennis, A.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001014387	A1	20010301
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US23334	A	20000824
PRIORITY INFO.:	US 1999-60/150,447		19990824
ABEN	Methods and materials involving 28-epirapamycin analogs are disclosed.		
ABFR			

L48 ANSWER 29 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001012659 PCTFULL ED 20020828
TITLE (ENGLISH): HUMAN DNA SEQUENCES
TITLE (FRENCH): SEQUENCE D'ADN HUMAIN
INVENTOR(S): WIEMANN, Stefan
PATENT ASSIGNEE(S): GERMAN HUMAN GENOME PROJECT; WIEMANN, Stefan
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001012659	A2	20010222
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-IB1496	A	20000818
PRIORITY INFO.:	US 1999-60/149,499		19990818
	US 1999-60/156,503		19990928

ABEN Novel human cDNA sequence of a clones, the encoded protein sequence of a clones, antibodies and variants thereof, are provided. The disclosed sequence of a clones find application in a number of ways, including use in profiling assays. In this regard, various assemblages of nucleic acids or proteins are provided that are useful in providing large arrays of human material for implementing large-scale screening strategies. The disclosed sequence of a clones may also be used in formulating medicaments, treating various disorders and in certain diagnostic applications.

ABFR

L48 ANSWER 30 OF 48 EUROPATFULL COPYRIGHT 2002 WILA
PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1130094 EUROPAFULL EW 200136 FS OS
 TITLE: Primers for synthesizing full length cDNA clones and their use.
 Primer zur Synthese von vollstaendigen cDNA Klonen und ihre Verwendung.
 Amorces pour la synthese de cADN de pleine longueur et leur utilisation.
 INVENTOR(S): Ota, Toshio, 1-2-7-105, Tsujido Shinmachi, Fujisawa-shi, Kanagawa 251-0042, JP;
 Nishikawa, Tetsuo, 27-3-403, Hikawa-cho, Itabashi-ku, Tokyo 173-0013, JP;
 Isogai, Takao, 511-12, Ohmuro, Ami-machi, Inashiki-gun, Ibaraki 300-0303, JP;
 Hayashi, Koji, 1-9-446, Yushudai Nishi, Ichihara-shi, Chiba 299-0125, JP;
 Ishii, Shizuko, 4508-19-202, Yana, Kisarazu-shi, Chiba 292-0812, JP;
 Kawai, Yuri, 4508-19-201, Yana, Kisarazu-shi, Chiba 292-0812, JP;
 Wakamatsu, Ai, 1473-4-202, Takayanagi, Kisarazu-shi, Chiba 292-0014, JP;
 Sugiyama, Tomoyasu, 2-6-23-102, Kiyomidai, Kisarazu-shi, Chiba 292-0045, JP;
 Nagai, Keiichi, 3-44-14-9-204, Sakuragaoka, Higashiyamato-shi, Tokyo 207-0022, JP;
 Kojima, Shinichi, 2-7-10-202, Gion, Kisarazu-shi, Chiba 292-0052, JP;
 Otsuki, Tetsuji, 3-1-10-B102, Asahi, Kisarazu-shi, Chiba 292-0055, JP;
 Koga, Hisashi, 2-4-15, Asahi, Kisarazu-shi, Chiba 292-0055, JP
 PATENT ASSIGNEE(S): Helix Research Institute, 1532-3 Yana, Kisarazu-shi, Chiba 292-0812, JP
 PATENT ASSIGNEE NO: 2656450
 AGENT: VOSSIUS & PARTNER, Siebertstrasse 4, 81675 Muenchen, DE
 AGENT NUMBER: 100314
 OTHER SOURCE: BEPA2001070 EP 1130094 A2 1381
 SOURCE: Wila-EPZ-2001-H36-T1a
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1130094	A2	20010905
		20010905
EP 2000-114089		20000707
JP 1999-1944861999		19990708
JP 2000-2000118774		20000111
JP 2000-2000183765		20000502

L48 ANSWER 31 OF 48 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI
 ACCESSION NUMBER: 2002-03511 BIOTECHDS
 TITLE: Improving stability and/or solubility of proteins expressed in vivo or in vitro;
 vector pEC1-1 expression Escherichia coli useful for protein engineering
 AUTHOR: Sanders M C
 PATENT ASSIGNEE: Expressive-Constructs
 LOCATION: Worcester, MA, USA.
 PATENT INFO: WO 2001083804 8 Nov 2001

APPLICATION INFO: WO 2001-US14692 3 May 2001

PRIORITY INFO: US 2000-201407 3 May 2000

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2002-011413 [01]

AN 2002-03511 BIOTECHDS

AB Methods for improving protein stability or solubility, are claimed. Also claimed are: a method (I) for producing a soluble and active recombinant protein; a method (II) for preventing unwanted proteolysis of a recombinant protein; a method for **purifying** native cattle **alpha-crystallin** protein; a method of **purifying** recombinant **alpha-crystallin** type **HIS-tagged** proteins; and a method (V) for protecting a protein from proteolysis during **purification**. The methods are used to improve protein stability, folding or solubility when produced either in vivo or in vitro. (23pp)

L48 ANSWER 32 OF 48 USPATFULL

ACCESSION NUMBER: 2000:160780 USPATFULL

TITLE: Synthetic transcriptional modulators and uses thereof

INVENTOR(S): Verdine, Gregory L., 91 Outlook Dr., Lexington, MA, United States 02173
Nyanguile, Origene, 2517 Baltimore Rd. #4, Rockville, MD, United States 20853

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153383		20001128
APPLICATION INFO.:	US 1997-987912		19971209 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot LLP, Vincent, Matthew P., Clauss, Isabelle M.		

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)

LINE COUNT: 2897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 33 OF 48 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2000061621 PCTFULL ED 20020515

TITLE (ENGLISH): FLEA HEAD, NERVE CORD, HINDGUT AND MALPIGHIAN TUBULE

TITLE (FRENCH): MOLECULES D'ACIDES NUCLEIQUES ET PROTEINES ISSUES DE LA TETE, DE LA MOELLE EPINIERE, DE L'INTESTIN POSTERIEUR ET DU TUBE DE MALPIGHI DE PUCES ET UTILISATIONS CORRESPONDANTES

INVENTOR(S): BRANDT, Kevin, S.; GAINES, Patrick, J.; STINCHCOMB, Dan, T.; WISNEWSKI, Nancy

PATENT ASSIGNEE(S): HESKA CORPORATION

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000061621	A2	20001019

DESIGNATED STATES AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML
MR NE SN TD TG

APPLICATION INFO.: WO 2000-US9437 A 20000407

PRIORITY INFO.: US 1999-60/128,704 19990409

ABEN The present invention relates to flea head, nerve cord, hindgut and malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation. Also included in the present invention is the use of flea head, nerve cord, hindgut and Malpighian tubule proteins to derive inhibitory compounds.

ABFR La presente invention se rapporte a des proteines issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de Malpighi de puces, a des molecules d'acides nucleiques issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de Malpighi de puces, et notamment des molecules d'acides nucleiques qui codent pour ces proteines de la tete, la moelle epiniere, l'intestin posterieur et le tube de Malpighi de puces, ainsi qu'a des anticorps diriges contre l'activite des proteines de la tete, la moelle epiniere, l'intestin posterieur et le tube de Malpighi de puces. La presente invention se rapporte egalement a des procedes permettant de produire ces proteines, molecules d'acides nucleiques, anticorps et composees inhibiteurs. Elle se rapporte egalement a des compositions therapeutiques comportant des proteines, des molecules d'acides nucleiques ou des composees protecteurs derives des proteines decrites ci-dessus ainsi qu'a l'utilisation de ces compositions therapeutiques pour proteger des animaux contre l'infestation par des puces. La presente invention se rapporte en outre a l'utilisation de proteines issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de Malpighi de puces pour produire des composees inhibiteurs.

L48 ANSWER 34 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000028011 PCTFULL ED 20020515
TITLE (ENGLISH): FK506-BASED REGULATION OF BIOLOGICAL EVENTS
TITLE (FRENCH): REGULATION FONDEE SUR FK506 D'EVENEMENTS BIOLOGIQUES
INVENTOR(S): CLEMONS, Paul, A.; GLADSTONE, Brian, G.; SETH, Abhinav;
SCHREIBER, Stuart, L.

PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE; CLEMONS,
Paul, A.; GLADSTONE, Brian, G.; SETH, Abhinav;
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000028011	A2	20000518
DESIGNATED STATES	AU CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU		
	MC NL PT SE		

APPLICATION INFO.: WO 1999-US25766 A 19991105
PRIORITY INFO.: US 1998-60/107,473 19981106

ABEN This invention provides methods and materials for making and using genetically engineered cells which are responsive to the presence of an FKBP/CAB ligand or a cyclophilin/CAB ligand. The invention relies upon the introduction into cells of recombinant DNAs encoding fusion proteins which are capable of forming a complex with each other in the presence of ligand. One of the fusion proteins contains a calcineurin A/calcineurin B domain (CAB) and at least one heterologous protein domain. The second fusion protein contains a domain derived from an FKBP protein which is capable of binding to an FKBP/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein may alternatively contain a cyclophilin domain which is capable of binding cyclosporin or other cyclophilin/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein also contains at least one heterologous domain.

ABFR On decrit des matieres et des procedes qui permettent de reguler des evenements biologiques tels que la transcription de genes cibles et la croissance, la proliferation ou la differenciation de cellules genetiquement modifiees.

L48 ANSWER 35 OF 48 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1059354 EUROPATFULL EW 200050 FS OS
TITLE: Sequence-determined DNA fragments and corresponding polypeptides encoded thereby.
DNS-fragmente mit bestimmter Sequenz und die dadurch kodierte Polypeptide.

INVENTOR(S): Fragments d'ADN avec des sequences determinees et polypeptides encodees par lesdits fragments.
Alexandrov, Nickolai, 1404 Oak Trail St., Thousand Oaks, CA 91320, US;
Troukhan, Maxim E., 1675 Amberwood Dr. No. 2, South Pasadena, CA 91030, US

PATENT ASSIGNEE(S): Ceres Incorporated, 3007 Malibu Canyon Road, Malibu, CA 90265, US

PATENT ASSIGNEE NO: 2967260
AGENT: Bannerman, David Gardner et al., Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW, GB 28001

AGENT NUMBER: 28001
OTHER SOURCE: BEPA2000096 EP 1059354 A2 0418

SOURCE: Wila-EPZ-2000-H50-T1a

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R

PATENT INFO.PUB.TYPE: SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFORMATION: EPA2 EUROPÄISCHE PATENTANMELDUNG

	PATENT NO	KIND DATE
	EP 1059354	A2 20001213
'OFFENLEGUNGS' DATE:		20001213
APPLICATION INFO.:	EP 2000-304943	20000612
PRIORITY APPLN. INFO.:	US 1999-138540	19990610
	US 1999-138847	19990610

L48 ANSWER 36 OF 48 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1033405 EUROPATFULL EW 200036 FS OS
TITLE: Sequence-determined DNA fragments and corresponding polypeptides encoded thereby.
DNS-fragmente mit bestimmter Sequenz und die dadurch kodierte Polypeptide.
Fragments d'ADN avec des sequences determinees et polypeptides encodees par lesdits fragments.
INVENTOR(S): Alexandrov, Nickolai, 1404 Oak Trail St., Thousand Oaks, CA 91320, US;
Brover, Vyacheslav, 5916 N. Las Virgenes Rd. #590, Calabasas, CA 91302, US;
Chen, Xianfeng, 1705 S. Westgate Ave. #2, Los Angeles, CA 90025, US;
Subramanian, Gopalakrishnan, 4205 Peach Slope Rd., Moorpark, CA 93021, US;
Troukhan, Maxim E., 1675 Amberwood Dr. #2, South Pasadena, CA 91030, US;
Zheng, Liansheng, 12333 Wild Turkey Court, #B, Creve Coeur, MO 63141, US;
Dumas, J., US
PATENT ASSIGNEE(S): Ceres Incorporated, 3007 Malibu Canyon Road, Malibu, CA 90265, US
PATENT ASSIGNEE NO: 2967260
AGENT: Bannerman, David Gardner et al., Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW, GB
AGENT NUMBER: 28001
OTHER SOURCE: BEPA2000068 EP 1033405 A2 0344
SOURCE: Wila-EPZ-2000-H36-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA2 EUROPÄISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1033405	A2 20000906
'OFFENLEGUNGS' DATE:		20000906
APPLICATION INFO.:	EP 2000-301439	20000225
PRIORITY APPLN. INFO.:	US 1999-121825	19990225
	US 1999-123180	19990305
	US 1999-123548	19990309
	US 1999-125788	19990323
	US 1999-126264	19990325
	US 1999-126785	19990329
	US 1999-127462	19990401
	US 1999-128234	19990406
	US 1999-128714	19990408
	US 1999-129845	19990416

US 1999-130077	19990419
US 1999-130449	19990421
US 1999-130891	19990423
US 1999-130510	19990423
US 1999-131449	19990428
US 1999-132407	19990430
US 1999-132048	19990430
US 1999-132484	19990504
US 1999-132485	19990505
US 1999-132487	19990506
US 1999-132486	19990506
US 1999-132863	19990507
US 2000-176866	20000119
US 2000-176867	20000119
US 2000-176910	20000119
US 2000-178166	20000126
US 2000-178545	20000127
US 2000-178547	20000127
US 2000-177666	20000127
US 2000-178546	20000127
US 2000-178544	20000127
US 2000-178754	20000128
US 2000-178755	20000128
US 2000-179388	20000201
US 2000-179395	20000201
US 2000-180139	20000203
US 2000-180039	20000203
US 2000-180206	20000204
US 2000-180207	20000204
US 2000-180696	20000207
US 2000-180695	20000207
US 2000-181214	20000209
US 2000-181228	20000209
US 2000-181551	20000210
US 2000-181476	20000210
US 2000-182478	20000215
US 2000-182477	20000215
US 2000-182516	20000215
US 2000-182512	20000215
US 2000-183166	20000217
US 2000-183165	20000217

L48 ANSWER 37 OF 48 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1999042118 PCTFULL ED 20020515

TITLE (ENGLISH): COMPOUNDS AND METHODS FOR DIAGNOSIS OF TUBERCULOSIS

TITLE (FRENCH): COMPOSES ET METHODES POUR DIAGNOSTIQUER LA TUBERCULOSE

INVENTOR(S): REED, Steven, G.; SKEIKY, Yasir, A., W.; DILLON, Davin, C.; CAMPOS-NETO, Antonio; HOUGHTON, Raymond; VEDVICK, Thomas, S.; TWARDZIK, Daniel, R.; LODES, Michael, J.; HENDRICKSON, Ronald, C.

PATENT ASSIGNEE(S): CORIXA CORPORATION

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 9942118	A2	19990826
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US3265	A	19990217

PRIORITY INFO.: US 1998-09/024,753 19980218
US 1998-09/072,596 19980505

L48 ANSWER 38 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999042076 PCTFULL ED 20020515
TITLE (ENGLISH): COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS
OF TUBERCULOSIS
TITLE (FRENCH): COMPOSES ET METHODES POUR L'IMMUNOTHERAPIE ET LE
DIAGNOSTIC DE LA TUBERCULOSE
INVENTOR(S): REED, Steven, G.; SKEIKY, Yasir, A., W.; DILLON, Davin,
C.; CAMPOS-NETO, Antonio; HOUGHTON, Raymond; VEDVICK,
Thomas, S.; TWARDZIK, Daniel, R.; LODES, Michael, J.;
HENDRICKSON, Ronald, C.
PATENT ASSIGNEE(S): CORIXA CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9942076	A2	19990826
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US3268	A	19990217
PRIORITY INFO.:	US 1998-09/025,197		19980218
	US 1998-09/072,967		19980505

ABEN Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more i(M. tuberculosis) proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against i(M. tuberculosis) infection, or may be used for the diagnosis of tuberculosis.

ABFR L'invention concerne des composes et des methodes destines a induire une immunité protectrice contre la tuberculose. Les composes de cette invention renferment des polypeptides contenant au moins une partie immunogene d'une ou plusieurs proteines de i(M. tuberculosis) et molecules d'ADN codant pour ces polypeptides. Ces composes peuvent entrer dans la composition de vaccins et/ou de compositions pharmaceutiques pour une immunisation contre toute infection a i(M. tuberculosis), ou etre utilises pour diagnostiquer la tuberculose.

L48 ANSWER 39 OF 48 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999041258 PCTFULL ED 20020515
TITLE (ENGLISH): NOVEL DIMERIZING AGENTS, THEIR PRODUCTION AND USE
TITLE (FRENCH): AGENTS DE DIMERISATION, PRODUCTION ET UTILISATION
INVENTOR(S): SCHREIBER, Stuart, L.; CRABTREE, Gerald, R.; LIBERLES,
Stephen, D.
PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9941258	A1	19990819

DESIGNATED STATES AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE

APPLICATION INFO.: WO 1999-US3095 A 19990212

PRIORITY INFO.: US 1998-60/074,584 19980213

ABEN Materials and methods are disclosed for regulation of biological events
such as target gene
transcription and growth, proliferation or differentiation of engineered
cells.

ABFR L'invention concerne des agents et des procedes permettant de reguler un
certain nombre
d'evenements biologiques, comme la transcription et la croissance de
genes cibles, ou la
proliferation et la differenciation de cellules manipulees.

L48 ANSWER 40 OF 48 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1999036553 PCTFULL ED 20020515

TITLE (ENGLISH): REGULATION OF BIOLOGICAL EVENTS USING MULTIMERIC
CHIMERIC PROTEINS

TITLE (FRENCH): REGULATION DE PHENOMENES BIOLOGIQUES AU MOYEN DE
PROTEINES CHIMERES MULTIMERES

INVENTOR(S): CLACKSON, Timothy, P.; GILMAN, Michael, Z.; HOLT,
Dennis, A.; KEENAN, Terence, P.; ROZAMUS, Leonard;
YANG, Wu

PATENT ASSIGNEE(S): ARIAD GENE THERAPEUTICS, INC.; CLACKSON, Timothy, P.;
GILMAN, Michael, Z.; HOLT, Dennis, A.; KEENAN, Terence,
P.; ROZAMUS, Leonard; YANG, Wu

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9936553	A2	19990722

DESIGNATED STATES AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1999-US178 A 19990115

PRIORITY INFO.: US 1998-60/071,591 19980115
US 1998-60/072,016 19980121
US 1998-60/072,219 19980122
US 1998-09/012,097 19980122

ABEN Materials and methods are disclosed for regulation of biological events
such as target gene
transcription and growth, proliferation or differentiation of engineered
cells.

ABFR L'invention concerne des matieres et des procedes servant a reguler des
phenomenes biologiques
tels que la transcription et la croissance d'un gene cible, la
proliferation ou la differenciation
de cellules mises au point genetiquement.

L48 ANSWER 41 OF 48 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1999030164 PCTFULL ED 20020515

TITLE (ENGLISH): METHOD TO IDENTIFY TRANSCRIPTIONAL MODULATORS

TITLE (FRENCH): PROCEDE D'IDENTIFICATION DE MODULATEURS DE
TRANSCRIPTION

INVENTOR(S): VERDINE, Gregory, L.; NYANGUILE, Origene

PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9930164 A1 19990617
 DESIGNATED STATES AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
 NL PT SE
 APPLICATION INFO.: WO 1998-US26101 A 19981209
 PRIORITY INFO.: US 1997-08/987,912 19971209
 ABEN Novel synthetic transcriptional modulators having at least one selected
 ligand linked to at
 least one transcriptional modulating portion are described. The
 transcriptional modulators of the
 present invention can include a ligand linked to a chemical moiety.
 These transcriptional modulators
 can be used to selectively control gene expression and to identify
 components of the transcriptional
 machinery.
 ABFR L'invention porte sur de nouveaux modulateurs de transcription de
 synthese presentant au moins
 un ligand selectionne lie a au moins une portion modulant la
 transcription. Lesdits modulateurs, qui
 peuvent comporter un ligand lie a un fragment chimique, peuvent servir a
 reguler selectivement
 l'expression de genes et a identifier certains composants du mecanisme
 de transcription.

L48 ANSWER 42 OF 48 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 1999007860 PCTFULL ED 20020515
 TITLE (ENGLISH): IMMUNE RESPONSES AGAINST HPV ANTIGENS ELICITED BY
 COMPOSITIONS COMPRISING AN HPV ANTIGEN AND A STRESS
 PROTEIN OR AN EXPRESSION **VECTOR** CAPABLE OF
 EXPRESSION OF THESE PROTEINS
 TITLE (FRENCH): REPONSES IMMUNITAIRES CONTRE LES ANTIGENES DU VPH ET
 DECLENCHEES PAR DES COMPOSITIONS COMPRENANT UN ANTIGENE
 DU VPH, ET PROTEINE DU STRESS OU VECTEUR D'EXPRESSION
 CAPABLE D'EXPRIMER CES PROTEINES
 INVENTOR(S): MIZZEN, Lee; CHU, Randall
 PATENT ASSIGNEE(S): STRESSGEN BIOTECHNOLOGIES CORPORATION; MIZZEN, Lee;
 CHU, Randall
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 9907860	A1	19990218
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-CA246	A	19980320
PRIORITY INFO.:	US 1997-60/054,835		19970805
ABEN	The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress		

protein sequences. In another embodiment, compositions comprise an expression **vector** including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression **vector** can be introduced into cells of a subject, or it can be used to transduce cells of the subject i(ex vivo), resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression **vectors** encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

ABFR La presente invention concerne des compositions permettant d'induire une reponse immunitaire, de preference une reponse immunitaire cellulaire de type II, et plus particulierement a mediation cellulaire, contre les antigenes du Virus des Papillomes Humains (VPH) que montre le VPH, ou que montrent des cellules infectees des tumeurs du col de l'uterus et d'autres tumeurs. Une realisation de l'invention porte sur des compositions comprenant une proteine antigene du VPH jointe a une proteine du stress (Hsp). L'antigene du VPH peut etre joint a une proteine du stress par conjugaison chimique ou par non-covalence en utilisant des groupes fonctionnels de liaison. Mais l'antigene du VPH peut egalement etre joint dans une proteine hybride contenant d'une part l'antigene du VPH, et d'autre part des sequences de proteine du stress. Une autre realisation porte sur des compositions comprenant un vecteur d'expression incluant, sous forme exprimable, des sequences codant pour l'antigene du VPH et des sequences codant pour la proteine du stress. Le vecteur d'expression peut etre introduit dans les cellules d'un sujet. Mais il peut egalement servir a la transduction de cellules du sujet i(ex vivo), ce qui aboutit a l'expression d'une proteine hybride proteine du stress - antigene du VPH qui doit normalement stimuler la reponse immunitaire du sujet a l'antigene du VPH. L'invention concerne egalement, non seulement des compositions comprenant une proteine du stress liee a un antigene du VPH et un autre composant pharmacologiquement acceptable, mais aussi des hybrides et des conjugues proteine du stress - antigene du VPH, et enfin des vecteurs d'expression codant pour et capable de diriger l'expression dans les cellules d'un sujet dans le cas d'une proteine hybride comprenant une proteine du stress et une sequence antigene du VPH. L'invention concerne enfin l'utilisation de ces compositions pour induire les reponses immunitaires contre le VPH et des cellules montrant l'antigene VPH, y compris les tumeurs liees au VPH.

L48 ANSWER 43 OF 48 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 1998016646 PCTFULL ED 20020514
 TITLE (ENGLISH): COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
 TITLE (FRENCH): COMPOSES ET METHODES UTILISES POUR L'IMMUNOTHERAPIE ET LE DIAGNOSTIC DE LA TUBERCULOSE
 INVENTOR(S): REED, Steven, G.; SKEIKY, Yasir, A., W.; DILLON, Davin, C.; CAMPOS-NETO, Antonio; HOUGHTON, Raymond; VEDVICK, Thomas, S.; TWARDZIK, Daniel, R.; LODES, Michael, J.
 PATENT ASSIGNEE(S): CORIXA CORPORATION
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9816646	A2	19980423
DESIGNATED STATES	AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US18293	A	19971007
PRIORITY INFO.:	US 1996-8/730,510		19961011
	US 1997-8/818,112		19970313

ABEN Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

ABFR L'invention concerne des composes et des methodes destines a induire une immunité contre la tuberculose. Ces composes comprennent des polypeptides qui contiennent au moins une partie immunogene d'une ou plusieurs proteines de M. tuberculosis et des molecules d'ADN codant ces polypeptides. De tels composes peuvent etre prepares sous forme de vaccins et/ou de compositions pharmaceutiques qui servent a immuniser un patient contre une infection provoquee par M. tuberculosis ou a diagnostiquer la tuberculose.

L48 ANSWER 44 OF 48 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 1998016645 PCTFULL ED 20020514
 TITLE (ENGLISH): COMPOUNDS AND METHODS FOR DIAGNOSIS OF TUBERCULOSIS
 TITLE (FRENCH): COMPOSES ET PROCEDES POUR DIAGNOSTIQUER LA TUBERCULOSE
 INVENTOR(S): REED, Steven, G.; SKEIKY, Yasir, A., W.; DILLON, Davin, C.; CAMPOS-NETO, Antonio; HOUGHTON, Raymond; VEDVICK, Thomas, S.; TWARDZIK, Daniel, R.; LODES, Michael, J.
 PATENT ASSIGNEE(S): CORIXA CORPORATION
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9816645	A2	19980423
DESIGNATED STATES	AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG		

SI SK SL TJ TM TR TT UA UG UZ VN YU GH KE LS MW SD SZ
 UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI
 FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
 ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US18214 A 19971007
 PRIORITY INFO.: US 1996-8/729,622 19961011
 US 1997-8/818,111 19970313

ABEN Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.

ABFR Cette invention porte sur des composes et des procedes servant a diagnostiquer la tuberculose. Les composes de l'invention comprennent des polypeptides contenant au moins une partie antigenique d'une ou plusieurs proteines de M. tuberculosis et des sequences d'ADN codant lesdits polypeptides. Des troussees de diagnostic contenant lesdits polypeptides ou sequences d'ADN et un reactif de depistage approprie peuvent etre utilises pour depister une infection M. tuberculosis chez des patients ou dans des echantillons biologiques. L'invention porte aussi sur des anticorps diriges contre lesdits polypeptides.

L48 ANSWER 45 OF 48 USPATFULL

ACCESSION NUMBER: 94:57739 USPATFULL
 TITLE: Process for synthesizing human H2-prorelaxin, human H2-relaxin and fusion proteins thereof
 INVENTOR(S): Hudson, Peter J., Bulleen, Australia
 Niall, Hugh D., Elwood, Australia
 Tregear, Geoffrey W., Hawthorn, Australia
 PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology and Medicine, Victoria, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5326694		19940705
APPLICATION INFO.:	US 1992-871318		19920420 (7)
DISCLAIMER DATE:	20050719		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-665129, filed on 6 Mar 1991, now patented, Pat. No. US 5179195 which is a division of Ser. No. US 1987-21885, filed on 4 Mar 1987, now patented, Pat. No. US 5023321 which is a division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented, Pat. No. US 4758516		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hill, Jr., Robert J.	
ASSISTANT EXAMINER:	Teng, Sally P.	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 10 Drawing Page(s)	

LINE COUNT: 1009

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer **vectors** for the expression of human preprorelaxin; sub-units thereof, including genes and transfer **vectors** for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 46 OF 48 USPATFULL

ACCESSION NUMBER: 93:3675 USPATFULL

TITLE: Human relaxin polypeptides

INVENTOR(S): Hudson, Peter J., Victoria, Australia

Niall, Hugh D., Victoria, Australia

Tregear, Geoffrey W., Victoria, Australia

PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology and Medicine, Melbourne, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5179195		19930112
APPLICATION INFO.:	US 1991-665129		19910306 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1987-21885, filed on 4 Mar 1987, now patented, Pat. No. US 5023321 which is a division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented, Pat. No. US 4758516		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lacey, David L.	
ASSISTANT EXAMINER:	Ossanna, Nina	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	992	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer **vectors** for the expression of human preprorelaxin; sub-units thereof, including genes and transfer **vectors** for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 47 OF 48 USPATFULL

ACCESSION NUMBER: 91:46779 USPATFULL

TITLE: Molecular cloning and characterization of a further gene sequence coding for human relaxin

INVENTOR(S): Hudson, Peter J., Bulleen, Australia

Niall, Hugh D., Elwood, Australia

Tregear, Geoffrey W., Hawthorn, Australia

PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology & Medicine, Victoria, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5023321		19910611
APPLICATION INFO.:	US 1987-21885		19870304 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented, Pat. No. US 4758516

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Moskowitz, Margaret	
ASSISTANT EXAMINER:	Ossanna, Nina	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	2	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	963	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer **vectors** for the expression of human preprorelaxin; sub-units thereof, including genes and transfer **vectors** for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 48 OF 48 USPATFULL

ACCESSION NUMBER: 88:45600 USPATFULL
TITLE: Molecular cloning and characterization of a further gene sequence coding for human relaxin
INVENTOR(S): Hudson, Peter J., Bulleen, Australia
Niall, Hugh D., Elwood, Australia
Tregear, Geoffrey W., Hawthorn, Australia
PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology and Medicine, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4758516		19880719
APPLICATION INFO.:	US 1983-560790		19831213 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wiseman, Thomas G.	
ASSISTANT EXAMINER:	Huleatt, Jayme A.	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak, and Seas	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	1017	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer **vectors** for the expression of human preprorelaxin; sub-units thereof, including genes and transfer **vectors** for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

=> s (alpha (w) crystallin) (s) bovine and (proteolysis or degradation or protease) and (preventing or prevent or inhibit?)

L49 3 FILE USPATFULL
L50 3 FILE PCTFULL
L51 6 FILE CAPLUS
L52 8 FILE BIOSIS
L53 5 FILE SCISEARCH
L54 11 FILE MEDLINE
L55 10 FILE EMBASE
L56 0 FILE TOXCENTER
L57 3 FILE EUROPATFULL
L58 2 FILE ESBIODBASE
L59 0 FILE GENBANK
L60 2 FILE BIOTECHNO
L61 0 FILE DRUGU
L62 2 FILE PASCAL
L63 1 FILE IFIPAT
L64 1 FILE WPIDS
L65 0 FILE AGRICOLA
L66 0 FILE BIOBUSINESS
L67 0 FILE BIOTECHDS
L68 0 FILE CABA
L69 0 FILE JICST-EPLUS
L70 1 FILE LIFESCI

TOTAL FOR ALL FILES

L71 58 (ALPHA (W) CRYSTALLIN) (S) BOVINE AND (PROTEOLYSIS OR DEGRADATIO
N OR PROTEASE) AND (PREVENTING OR PREVENT OR INHIBIT?)

=> dup rem l71

DUPLICATE IS NOT AVAILABLE IN 'GENBANK'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L71

L72 26 DUP REM L71 (32 DUPLICATES REMOVED)

=> d l72 1-26 ibib abs

L72 ANSWER 1 OF 26 USPATFULL

DUPLICATE 1

ACCESSION NUMBER: 2002:258814 USPATFULL

TITLE: Method and device for improving protein stability and solubility

INVENTOR(S): Sanders, Mitchell C., Leicester, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142384	A1	20021003
APPLICATION INFO.:	US 2001-848780	A1	20010503 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201407P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the mutiple cloning site of the PROTECT Vector System just downstream of the p26 or alpha crystallin

type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac I.sub.q). The soluble recombinant protein is purified using a fusion tag.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L72 ANSWER 2 OF 26 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002010433 PCTFULL ED 20020814
TITLE (ENGLISH): A DEVICE FOR DETECTING BACTERIAL CONTAMINATION AND
METHOD OF USE
TITLE (FRENCH): DISPOSITIF DE DETECTION DE CONTAMINATION BACTERIENNE ET
PROCEDE D'UTILISATION
INVENTOR(S): SANDERS, Mitchell, C.
PATENT ASSIGNEE(S): EXPRESSIVE CONSTRUCTS, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002010433	A2	20020207
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US14613	A	20010503
PRIORITY INFO.:	US 2000-60/201,405		20000503

ABEN A device and method for detecting the presence or absence of a prokaryotic microorganism are provided, comprising the steps of identifying a protein, such as a microbial-specific **protease** that characterizes the presence of a specific prokaryotic microbe and thereby provides a marker for that microbe; detecting the **protease** that is a marker for the presence of a specific prokaryotic microbe by cleaving a substance when the **protease** is present; and signaling the presence of that **protease** when cleavage has occurred. More specifically, the method comprises identifying at least one outer membrane protein or a secreted protein that is unique to a particular microbial pathogen such as for example *Listeria monocytogenes* and that is substrate specific.

ABFR L'invention concerne un dispositif et un procede de detection de la presence ou de l'absence de micro-organisme procaryote, le procede consistant a identifier une proteine, telle qu'une **protease** microbienne qui caracterise la presence d'un microbe procaryote specifique et fournit ainsi un marqueur pour ce microbe, a detecter la **protease** marqueur revelant la presence d'un microbe procaryote specifique par clivage d'une substance lorsque la **protease** est presente, et a signaler la presence de cette **protease** lorsque le clivage est realise. Le procede consiste, plus specifiquement, a identifier au moins une proteine de membrane exterieure ou une proteine secretee, unique d'un pathogene microbien particulier tel que, par exemple, *Listeria monocytogenes* et qui presente une specificite de substrat.

L72 ANSWER 3 OF 26 MEDLINE
ACCESSION NUMBER: 2002216779 MEDLINE
DOCUMENT NUMBER: 21950077 PubMed ID: 11952403
TITLE: Chaperone activity in the lens.
AUTHOR: Augusteyn Robert C; Murnane Letitia; Nicola Andrea; Stevens Arthur
CORPORATE SOURCE: National Vision Research Institute of Australia, 386 Cardigan Street, Carlton VIC 3053, Australia.
SOURCE: Clin Exp Optom, (2002 Mar) 85 (2) 83-90.

Journal code: 8703442. ISSN: 0816-4622.
PUB. COUNTRY: Australia
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200207
ENTRY DATE: Entered STN: 20020416
Last Updated on STN: 20020709
Entered Medline: 20020708

AB INTRODUCTION: **alpha-crystallin**, the major protein of the eye lens, is a molecular chaperone that is able to **prevent** the precipitation of denatured proteins. This activity is thought to be important for the maintenance of lens transparency. Loss of the activity has been postulated to contribute to the development of cataract. The purpose of this study was to determine how chaperone activity was affected by growth and ageing of the lens. METHODS: **alpha-crystallins** were purified from nine concentric tissue layers removed from an adult **bovine** lens. The ability to **inhibit** the precipitation of beta(L)-crystallin, following thermal denaturation, was used to assess the chaperone activity of these proteins. The molar ratio of **alpha-crystallin**/beta(L)-crystallin required to **inhibit** the precipitation of beta(L)-crystallin by 50 per cent was used as a measure of the affinity of the chaperone for denatured protein. RESULTS: As evidenced by a gradual increase in the ratio, from 0.52 to 1.24, the protective ability of **alpha-crystallin** decreased from the outside of the lens into the centre. **alpha-crystallin** from the cortex of the lens provided greater protection against precipitation of proteins than older **alpha-crystallin** from the nucleus. The reasons for this were investigated. Gel electrophoresis of the proteins from each concentric layer revealed an increase in degraded polypeptides from approximately one per cent in the cortex to more than nine per cent in the centre of the lens. This increase appears to be correlated with the decrease in chaperone ability. Renaturing **alpha-crystallin** obtained from the nucleus did not increase its chaperone activity, indicating conformational changes were not responsible for the decreased activity. Phosphorylation did not appear to have any significant effect on the chaperone activity. CONCLUSION: The loss of chaperone activity, accompanying fibre cell compression into the centre of the lens, can be attributed to **degradation** of the **alpha-crystallin** polypeptides.

L72 ANSWER 4 OF 26 PCTFULL COPYRIGHT 2002 UniventioDUPLICATE 2
ACCESSION NUMBER: 2001083804 PCTFULL ED 20020826
TITLE (ENGLISH): A METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND SOLUBILITY
TITLE (FRENCH): METHODE ET DISPOSITIF POUR AMELIORER LA STABILITE ET LA SOLUBILITE DE PROTEINES
INVENTOR(S): SANDERS, Mitchell, C.
PATENT ASSIGNEE(S): EXPRESSIVE CONSTRUCTS, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001083804	A2	20011108
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US14692	A	20010503
PRIORITY INFO.:	US 2000-60/201,407		20000503

ABEN A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as *E. Coli* is provided. Genes of interest are cloned into the multiple cloning site of the pPROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1mMIPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.

ABFR L'invention concerne une methode servant a exprimer des proteines en tant que chimere de fusion presentant un domaine proteique de type p26 ou alpha-crystallin, destinee a ameliorer la stabilite et la solubilite des proteines lorsqu'elles sont exprimees excessivement dans des bacteries telles que *E. Coli*. Des genes d'interet sont clones dans le site de clonage multiple du systeme vectorette pPROTECT juste en aval de la proteine de type p26 ou alpha-crystallin et d'un site de clivage de thrombine. L'expression proteique est effectuee par un puissant promoteur bacterien (TAC). Cette expression est induite par l'addition de 1mMIPTG qui surmonte la repression de lac (lac Iq). La proteine recombinante soluble est purifiee au moyen d'un fragment de fusion.

L72 ANSWER 5 OF 26 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2001057190 PCTFULL ED 20020827
 TITLE (ENGLISH): NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
 TITLE (FRENCH): ACIDES NUCLEIQUES ET POLYPEPTIDES
 INVENTOR(S): TANG, Y., Tom; LIU, Chenghua; DRMANAC, Radoje, T.; ASUNDI, Vinod; ZHOU, Ping; XU, Chongjun; CAO, Yicheng; MA, Yunqing; ZHAO, Qing, A.; WANG, Dunrui; WANG, Jian-Rui; ZHANG, Jie; REN, Feiyan; CHEN, Rui-hong; WANG, Zhi, Wei; XUE, Aidong, J.; YANG, Yonghong; WEJHRMAN, Tom; GOODRICH, Ryle
 PATENT ASSIGNEE(S): HYSEQ, INC.; TANG, Y., Tom; LIU, Chenghua; DRMANAC, Radoje, T.; ASUNDI, Vinod; ZHOU, Ping; XU, Chongjun; CAO, Yicheng; MA, Yunqing; ZHAO, Qing, A.; WANG, Dunrui; WANG, Jian-Rui; ZHANG, Jie; REN, Feiyan; CHEN, Rui-hong; WANG, Zhi, Wei; XUE, Aidong, J.; YANG, Yonghong; WEJHRMAN, Tom; GOODRICH, Ryle
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001057190	A2	20010809
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US4098	A	20010205
PRIORITY INFO.:	US 2000-09/496,914		20000203
	US 2000-09/560,875		20000427
	US 2000-09/598,075		20000620
	US 2000-09/620,325		20000719
	US 2000-09/654,936		20000901
	US 2000-09/663,561		20000915
	US 2000-09/693,325		20001020
	US 2000-09/728,422		20001130

ABEN The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

ABFR L'invention concerne des acides nucleiques, des sequences polypeptidiques codees par ces acides nucleiques et leurs utilisations correspondantes.

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1130094 EUROPATFULL EW 200136 FS OS
 TITLE: Primers for synthesizing full length cDNA clones and their use.
 Primer zur Synthese von vollstaendigen cDNA Klonen und ihre Verwendung.
 Amorces pour la synthese de cADN de pleine longueur et leur utilisation.

INVENTOR(S): Ota, Toshio, 1-2-7-105, Tsujido Shinmachi, Fujisawa-shi, Kanagawa 251-0042, JP;
 Nishikawa, Tetsuo, 27-3-403, Hikawa-cho, Itabashi-ku, Tokyo 173-0013, JP;
 Isogai, Takao, 511-12, Ohmuro, Ami-machi, Inashiki-gun, Ibaraki 300-0303, JP;
 Hayashi, Koji, 1-9-446, Yushudai Nishi, Ichihara-shi, Chiba 299-0125, JP;
 Ishii, Shizuko, 4508-19-202, Yana, Kisarazu-shi, Chiba 292-0812, JP;
 Kawai, Yuri, 4508-19-201, Yana, Kisarazu-shi, Chiba 292-0812, JP;
 Wakamatsu, Ai, 1473-4-202, Takayanagi, Kisarazu-shi, Chiba 292-0014, JP;
 Sugiyama, Tomoyasu, 2-6-23-102, Kiyomidai, Kisarazu-shi, Chiba 292-0045, JP;
 Nagai, Keiichi, 3-44-14-9-204, Sakuragaoka, Higashiyamato-shi, Tokyo 207-0022, JP;
 Kojima, Shinichi, 2-7-10-202, Gion, Kisarazu-shi, Chiba 292-0052, JP;
 Otsuki, Tetsuji, 3-1-10-B102, Asahi, Kisarazu-shi, Chiba 292-0055, JP;
 Koga, Hisashi, 2-4-15, Asahi, Kisarazu-shi, Chiba 292-0055, JP

PATENT ASSIGNEE(S): Helix Research Institute, 1532-3 Yana, Kisarazu-shi, Chiba 292-0812, JP

PATENT ASSIGNEE NO: 2656450

AGENT: VOSSIUS & PARTNER, Siebertstrasse 4, 81675 Muenchen, DE

AGENT NUMBER: 100314

OTHER SOURCE: BEPA2001070 EP 1130094 A2 1381

SOURCE: Wila-EPZ-2001-H36-T1a

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1130094	A2	20010905
		20010905
EP 2000-114089		20000707
JP 1999-1944861999		19990708
JP 2000-2000118774		20000111
JP 2000-2000183765		20000502

ACCESSION NUMBER: 1999:132249 USPATFULL

TITLE: Healthy foods and cosmetics

INVENTOR(S): Yamaguchi, Fumio, Noda, Japan
 Saito, Makoto, Noda, Japan
 Ishikawa, Hiroharu, Noda, Japan

Kataoka, Shigehiro, Noda, Japan
Ariga, Toshiaki, Noda, Japan
PATENT ASSIGNEE(S): Kikkoman Corporation, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972357		19991026
APPLICATION INFO.:	US 1997-975713		19971121 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-353869	19961219
	JP 1997-199119	19970710
	JP 1997-199120	19970710

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Clardy, S. Mark
ASSISTANT EXAMINER: Williamson, Michael A.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to healthy foods and cosmetics. More particularly, it relates to healthy foods and cosmetics containing a polyisoprenylated benzophenone derivatives as effective ingredients and having a variety of functions for maintaining health such as anti-ulcer activity, the Maillard reaction **inhibiting** activity, anti-oxidation activity, reactive oxygen species scavenging activity, and anti-tumor promotion activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L72 ANSWER 8 OF 26 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 764273 EUROPATFULL EW 199842 FS PS
TITLE: ALPHA B CRYSTALLIN FOR USE IN DIAGNOSIS AND THERAPY OF AUTO-IMMUNE DISEASES IN PARTICULAR MULTIPLE SCLEROSIS. ALPHA B CRYSTALLIN ZUR VERWENDUNG IN DIAGNOSE UND THERAPIE VON AUTOIMMUNKRANKHEITEN, BESONDERS MULTIPLER SKEROSE. CRISTALLINE ALPHA B UTILISEE DANS LE DIAGNOSTIC ET LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET EN PARTICULIER LA SCLEROSE EN PLAQUE.
INVENTOR(S): VAN NOORT, Johannes, M., Lange Kleiweg 139, NL-2288 GJ Rijswijk, NL;
VAN SECHEL, Arianne, C., Lange Kleiweg 139, NL-2288 GJ Rijswijk, NL;
OUAGMIRI, Mustapha, El, Lange Kleijweg 139, NL-2288 GJ Rijswijk, NL
PATENT ASSIGNEE(S): NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO, Juliana van Stolberglaan 148, 2595 CL Den Haag, NL
PATENT ASSIGNEE NO: 285523
AGENT: Smulders, Theodorus A.H.J., Ir. et al, Vereenigde Octrooibureaux Nieuwe Parklaan 97, 2587 BN 's-Gravenhage, NL
AGENT NUMBER: 21191
OTHER SOURCE: EPB1998056 EP 0764273 B1 981014
SOURCE: Wila-EPS-1998-H42-T2
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

PATENT INFO.PUB.TYPE: IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 764273	B1	19981014
'OFFENLEGUNGS' DATE:			19970326
APPLICATION INFO.:	EP 1995-920305		19950608
PRIORITY APPLN. INFO.:	EP 1994-201653		19940609
RELATED DOC. INFO.:	WO 95-NL203	950608	INTAKZ
	WO 9533997	951214	INTPNR
REF. NON-PATENT-LIT.:	AMERICAN JOURNAL OF PATHOLOGY, vol. 140, no. 2, February 1992 HAGERSTOWN MD, USA, pages 345-356, T. IWAKA ET AL. 'Accumulation of alphaB-crystallin in central nervous system glia and neurons in pathologic conditions.' cited in the application CELL, vol. 57, no. 1, 7 April 1989 CAMBRIDGE MA, USA, pages 71-78, T. IWAKI ET AL. 'alphaB-crystallin is expressed in non-lenticular tissues and accumulates in Alexander's disease brain.' AMERICAN JOURNAL OF PATHOLOGY, vol. 143, no. 2, August 1993 HAGERSTOWN MD, USA, pages 487-495, T. IWAKI ET AL. 'alphaB-crystallin and 27-kd heat shock protein are regulated by stress conditions in the central nervous system and accumulate in Rosenthal fibers.' cited in the application THE EMBO JOURNAL, vol. 13, no. 4, 15 February 1994 OXFORD, GB, pages 945-953, I. NICHOLL ET AL. 'Chaperone activity of alpha-crystallins modulates intermediate filament assembly.' cited in the application THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 11, 15 April 1992 BALTIMORE MD, USA, pages 7718-7725, K. KATO ET AL. 'Copurification of small heat shock protein with alphaB crystallin from human skeletal muscle.' THE JOURNAL OF IMMUNOLOGY, vol. 149, no. 4, 15 August 1992 BALTIMORE MD, USA, pages 1444-1451, R. SOBEL ET AL. 'The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein. T cell receptors in inflammatory lesions.'		

L72 ANSWER 9 OF 26 USPATFULL

ACCESSION NUMBER: 95:7820 USPATFULL

TITLE: Ubiquitin carrier enzyme E2-F1, purification, production, and use

INVENTOR(S): Ciechanover, Aaron J., Haifa, Israel
Blumenfeld, Nava, Haifa, Israel
Gonen, Hedva, Haifa, Israel

PATENT ASSIGNEE(S): Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5384255		19950124
APPLICATION INFO.:	US 1993-80073		19930621 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Prouty, Rebecca		
LEGAL REPRESENTATIVE:	Sterne, Kessler Goldstein & Fox		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2266		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	A method for isolating and purifying novel species of E2		

ubiquitin-carrier protein, designated E2-F1, is disclosed. A method for preparing enzymatically active fragments of E2-F1 enzyme is also disclosed. The use of purified E2-F1 to produce antibodies is also disclosed. The use of such E2-F1-specific antibodies to detect the presence of E2-F1 in a biological sample, and to **inhibit** protein **degradation** are also disclosed. Recombinant DNA molecules which code for E2-F1, and recombinant hosts and vectors which contain E2-F1 coding sequences are also disclosed. The use of such recombinant hosts and vectors to produce E2-F1 protein is also disclosed. The use of purified E2-F1 to identify and to isolate E3 enzyme is also disclosed. Methods for screening substances for the ability to **inhibit** E2-F1 enzyme activity are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L72 ANSWER 10 OF 26 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 654530 EUROPATFULL EW 199521 FS OS STA B
 TITLE: Ubiquitin carrier enzyme E2-F1, purification, production and use.
 Ubiquitin-Traegerenzym E2-F1, seine Reinigung, Herstellung und Verwendung.
 L'enzyme E2-F1, porteur d'ubiquitine, sa purification, sa production, et son utilisation.
 INVENTOR(S): Ciechanover, Aaron J., 21 Peretz Bernstein Street, Haifa 34981, IL;
 Blumenfeld, Nava, 33 Beth Lehem Street, Haifa 35566, IL;
 Gonen, Hevda, 1 Dr. Tzipor Street, Kiryat Haim, Haifa 26272, IL
 PATENT ASSIGNEE(S): RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCE, P.O.Box 9697, Haifa 31096, IL
 PATENT ASSIGNEE NO: 1801090
 AGENT: Dr. Fuchs, Dr. Luderschmidt Dr. Mehler, Dipl.-Ing. Weiss
 Patentanwalte, Abraham-Lincoln-Strasse 7, D-65189 Wiesbaden, DE
 AGENT NUMBER: 100492
 OTHER SOURCE: ESP1995035 EP 0654530 A2 950524
 SOURCE: Wila-EPZ-1995-H21-T1a
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 654530	/	A2 19950524
'OFFENLEGUNGS' DATE:			19950524
APPLICATION INFO.:	EP 1994-109286		19940616
PRIORITY APPLN. INFO.:	US 1993-80073		19930621

L72 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3

ACCESSION NUMBER: 1995:933631 CAPLUS
 DOCUMENT NUMBER: 123:335891
 TITLE: Age-dependent association of isolated bovine lens multicatalytic proteinase complex (proteasome) with heat-shock protein 90, an endogenous **inhibitor**
 AUTHOR(S): Wagner, B. J.; Margolis, Joyce W.
 CORPORATE SOURCE: Dep. Biochem., Univ. Med. Dentistry-New Jersey Medical Sch., Newark, NJ, 07103, USA
 SOURCE: Archives of Biochemistry and Biophysics (1995), 323(2), 455-62
 CODEN: ABBIA4; ISSN: 0003-9861

PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The multicatalytic proteinase complex (MPC) (proteasome) is a high-mol.-wt. proteolytic enzyme found in eukaryotic cells and archaeobacteria. Regulatory proteins that **inhibit** or activate the MPC have been described. Assocn. with an ATPase complex alters the specificity of the multicatalytic proteinase complex to permit cleavage of ubiquitinated proteins. Unidentified proteins have been obsd. in highly purified preps. of the multicatalytic proteinase complex. Based on immunoreactivity and N-terminal sequencing, the authors have identified heat-shock protein 90 as a major component of the multicatalytic proteinase complex prepd. from 1-mo, but not 2-yr bovine lenses. .alpha.-Crystallin, a lens structural protein with chaperone activity, is also found in multicatalytic proteinase complex preps. Both heat-shock protein 90 and .alpha.-crystallin **inhibit** hydrolysis of Cbz-Leu-Leu-Leu-MCA by the multicatalytic proteinase complex as a stoichiometry of 1 mol heat-shock protein per mol of MPC. Heat-shock proteins may interact with denatured proteins and facilitate their **degrdn**. These studies give evidence for the involvement of heat-shock proteins in **proteolysis** by direct interaction with the multicatalytic proteinase complex.

L72 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4

ACCESSION NUMBER: 1995:689635 CAPLUS

DOCUMENT NUMBER: 123:108671

TITLE: **Degradation** of differentially oxidized .
alpha.-crystallins in **bovine**
lens epithelial cells

AUTHOR(S): Huang, Li L.; Shang, Fu; Nowell, Thomas R., Jr.;
Taylor, Allen

CORPORATE SOURCE: USDA Human Nutrition Res. Cent. Aging, Tufts Univ.,
Boston, MA, USA

SOURCE: Experimental Eye Research (1995), 61(1), 45-54
CODEN: EXERA6; ISSN: 0014-4835

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB There is a growing consensus that altered proteins are more susceptible to **degrdn**. than native proteins. The enhancement of **degrdn** . of damaged proteins may be of significance since it **prevents** the accumulation of damaged proteins in cells. Several proteolytic pathways have been discovered in the lens. These include ATP-independent, ATP-dependent and ATP/ubiquitin-dependent proteolytic pathways. However, the extent of involvement of these proteolytic pathways in **degrdn** . of damaged proteins is not well described. .alpha.-Crystallin was oxidized by exposure to 0.03-3.2 mol .bul.OH (mol protein)-1. Modifications to the oxidized .alpha.-crystallin and proteolytic susceptibility of the oxidized .alpha.-crystallin were studied. Exposure to > 0.32 mol .bul.OH per mol of subunit produced aggregates and fragments of .alpha.-crystallin. Changes in isoelec. points of the proteins were obsd. after exposure to 0.64 mol .bul.OH (mol protein)-1. The extent of loss of tryptophan and sulfhydryl groups was related to the level of .bul.OH-exposure. Carbonyl content increased progressively with increasing oxidn. When incubated with a supernatant of **bovine** lens epithelial cells, the .bul.OH-modified proteins were proteolytically degraded up to three times faster than untreated **.alpha.-crystallin**. ATP stimulated the **degrdn**. of native .alpha.-crystallin and .alpha.-crystallin which was exposed to 1.6 mol .bul.OH (mol subunit protein)-1 (.alpha.1.6). Sixty-seven per cent and 100% of the ATP-dependent **degrdn**. of native .alpha.-crystallin and .alpha.1.6 was ubiquitin-dependent, resp. The data indicate that **.alpha.-crystallins** oxidized by .bul.OH are recognized and degraded rapidly by cytoplasmic proteolytic systems in **bovine** lens epithelial cells. Both ATP-independent and ATP/ubiquitin-dependent

proteolytic pathways are involved in the **degrdn.** of native and oxidized .alpha.-crystallin.

L72 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5
ACCESSION NUMBER: 1994:454254 CAPLUS
DOCUMENT NUMBER: 121:54254
TITLE: Characterization of denatured protein inducers of the heat shock (stress) response in *Xenopus laevis* oocytes
AUTHOR(S): Mifflin, Laura C.; Cohen, Robert E.
CORPORATE SOURCE: Dep. Chem. Biochem., Univ. California, Los Angeles, CA, 90024, USA
SOURCE: Journal of Biological Chemistry (1994), 269(22), 15710-17
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In addn. to thermal stress, a large variety of phys. and chem. treatments are known to induce heat shock gene expression. Denatured protein, thought to result from the stress condition, has been postulated to act as the common signal. Accordingly, of three pairs of native and denatured proteins injected into *Xenopus laevis* oocytes, only the denatured derivs. induced expression of a reporter gene from a heat shock promoter (Ananthan, J., et al., 1986). These observations are extended here. Protein denaturation per se is shown to be insufficient for heat shock induction; although reduced and carboxymethylated **bovine** serum albumin (rcm-BSA) and **.alpha.-crystallin** elicited a stress response, many other denatured proteins had no effect. Methylation of protein lysines, done to **prevent** ubiquitination, suppressed heat shock induction by rcm-BSA, but enhanced induction by **.alpha.-crystallin**. Thus, the potential for a protein to be ubiquitinated is independent of its ability to induce the stress response. Instead, aggregation distinguished the proteins that were effective stress inducers, and the formation of large aggregates correlated with the magnitude of the response. This correlation may derive in part from decreased in vivo **degrdn.** rates of the inducer proteins. An apparent requirement for stress response induction that the inducer proteins be injected directly into the oocyte nucleus may relate to this issue of in vivo stability. The dependence of the stress response on the amt. of injected protein is nonstress response on the amt. of injected protein is nonlinear and of a form consistent with the titrn. of a factor that otherwise suppresses heat shock gene expression.

L72 ANSWER 14 OF 26 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 94268098 EMBASE
DOCUMENT NUMBER: 1994268098
TITLE: ~~A comparison of the inhibition of porcine pancreatic elastase and human neutrophil elastase by alpha-crystallin.~~
AUTHOR: Ortwerth B.J.; Krishna Sharma K.; Olesen P.R.
CORPORATE SOURCE: Mason Institute of Ophthalmology, University of Missouri, One Hospital Drive, Columbia, MO 65212, United States
SOURCE: ~~Current Eye Research, (1994) 13/8 (561-567).~~
ISSN: 0271-3683 CODEN: CEYRDM
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 012 Ophthalmology
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
AB **Bovine** lens **.alpha.-crystallin** **inhibited** both porcine pancreatic elastase (PPE) and human neutrophil elastase (HNE), but not in the same manner. PPE was immediately **inhibited** with a stoichiometry of 10 moles of PPE **inhibited** per mole of **.alpha.-crystallin**. The **inhibition** was markedly decreased by the addition of even low

levels of salts. The **inhibition** was transient, as PPE activity returned to normal with a $t(1/2)$ of 30 min even in low salt. HNE required a short preincubation to show maximum **inhibition** with a stoichiometry of approximately one mole of HNE **inhibited** per mole of **.alpha.-crystallin**. The **inhibition** of HNE was only slightly decreased by the addition of 0.1 M salt, and HNE activity returned slowly exhibiting a $t(1/2)$ of 30 hrs under these conditions. The **inhibition** of each enzyme by **.alpha.-crystallin** was evaluated by Dixon plots giving $K(i)$ values of 1.5 nM for PPE and 0.25 nM for HNE. DFP-trypsin was able to compete with PPE for binding to **.alpha.-crystallin** and cause the release of PPE already bound to **.alpha.-crystallin**. The **inhibition** of HNE, however, was unaffected by the addition of DFP-trypsin. A mixture of HNE and **.alpha.-crystallin** in 0.1 M NaCl was incubated at 25.degree.C for 6 hours. Aliquots showed a slow, continuous cleavage of the **.alpha.-crystallin** subunits by SDS-PAGE, but little or no increase in HNE activity. A similar experiment with PPE in 0.1 M NaCl showed no **inhibition** and a significant cleavage of **.alpha.-crystallin** after only one minute of incubation. These data argue for distinct **inhibitory** mechanisms and binding sites for these two elastase enzymes.

L72 ANSWER 15 OF 26 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1992:332584 BIOSIS

DOCUMENT NUMBER: BA94:34425

TITLE: THE EFFECT OF UREA ON THE AGGREGATE STATE AND ELASTASE INHIBITOR ACTIVITY OF THE WATER-INSOLUBLE FRACTION FROM BOVINE AND HUMAN LENS.

AUTHOR(S): ORTWERTH B J; SHARMA K K; OLESEN P R

CORPORATE SOURCE: MASON INST. OPHTHALMOL., DEP. BIOCHEM., UNIV. MO., COLUMBIA, MO. 65212.

SOURCE: EXP EYE RES, (1992) 54 (4), 573-581.

CODEN: EXERA6. ISSN: 0014-4835.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB Preparations of **.alpha.-crystallin** from bovine and human lens exhibited elastase **inhibitor** activity with a specific activity of 100-250 U mg-1 protein. A washed water-insoluble fraction from **bovine**, human and cataractous lens nuclei, when solubilized by sonication, gave specific activities of 910, 950 and 1270 U mg-1, respectively. Disaggregation of these water-insoluble fractions in 8.0 M urea, with subsequent reaggregation by urea removal, resulted in a decrease in **inhibitor** activity. Agarose A-5m gel filtration chromatography after the urea treatment resolved a residual high molecular weight (HMW) fraction and a peak which eluted at the position of water soluble **.alpha.-crystallin**. Assays showed that the urea-induced '**.alpha.-crystallin**' peaks from all three preparations had specific activities, equivalent to native **.alpha.-crystallin**, whereas the HMW fractions retained their original high specific activity. We conclude that the increased elastase **inhibitor** activity of the water-insoluble fraction is a property of the aggregate state of the component **.alpha.-crystallin** molecules, which is lost upon reaggregation to an 800-kDa **.alpha.-crystallin**. Amino acid analysis of the **bovine** water-insoluble fraction suggested a content of 85-90% **.alpha.-crystallin** and 10-15 **.beta.H-crystallin**, which was confirmed by SDS-PAGE. The urea-induced '**.alpha.-crystallin**' peak had an amino acid composition which was almost identical to that of water-soluble **.alpha.-crystallin** except for a 20% decrease in serine. The water-insoluble sonicate supernatant (WISS) fractions from normal human and cataractous lens nuclei had identical amino acid compositions, which were most similar to **.alpha.-crystallin** but as much as 30-40% of the WISS fraction was derived from other crystallins. The high **.alpha.-crystallin** content of the human water-insoluble fraction was

confirmed by the D2 spectrum of the sonication solubilized proteins. In spite of the fact that these proteins are extensively cross-linked, and contain low molecular weight peptides as well as other crystallins, these solubilized WI proteins reassembled into **.alpha.-crystallin**-sized molecules after dissociation by urea.

L72 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
ACCESSION NUMBER: 1992:146643 CAPLUS
DOCUMENT NUMBER: 116:146643
TITLE: Characterization of the elastase **inhibitor**
properties of **.alpha.-crystallin**
and the water-insoluble fraction from **bovine**
lens
AUTHOR(S): Ortwerth, B. J.; Olesen, P. R.
CORPORATE SOURCE: Mason Inst. Ophthalmol., Univ. Missouri, Columbia, MO,
65212, USA
SOURCE: Experimental Eye Research (1992), 54(1), 103-11
CODEN: EXERA6; ISSN: 0014-4835
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **.alpha.-Crystallin** exhibits variable **inhibition** of several members of the chymotrypsin family of proteinases. Complete **inhibition** of elastase was obtained by the addn. of either **.alpha.-crystallin** or a sonicated prepn. of the water-insol. fraction from **bovine** lens. Little or no **inhibition** was seen, however, with either **.beta.-crystallin** or bovine serum albumin under the same conditions. Complete binding of elastase was demonstrated by Sephadex G-100 gel filtration chromatog., and a direct correlation between binding and **inhibition** was obtained. This observation permitted a Scatchard anal. of the **inhibition** data. Scatchard plots for the binding of elastase gave a biphasic response suggesting two sep. binding sites. These sites had Kd values of 15 and 40 nM for **.alpha.-crystallin** and 6 and 42 nM for the **bovine** lens water-insol. fraction. Similarly, a Dixon plot exhibited a Ki value of 3 nM and was consistent with non-competitive **inhibition**. One mole of **.alpha.-crystallin** (8 .times. 105 Da), or an equiv. amt. of water-insol. protein, bound 13-19 mol of elastase and were about equally divided between the high and low affinity sites. Satn. studies confirmed 20 and 16 elastase binding sites per 8 .times. 105 Da for **.alpha.-crystallin** and water-insol. protein, resp. DFP-elastase (DFP = diisopropyl fluorophosphate) was able to bind to **.alpha.-crystallin**, suggesting that proteolytic cleavage was not required for complex formation. Stability measurements showed a linear return to 60% of the original activity over a 30-min period. Therefore, the interaction between elastase and **.alpha.-crystallin** resembles that of a heterologous **protease:inhibitor** complex in both binding and stability.

L72 ANSWER 17 OF 26 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 91111109 EMBASE
DOCUMENT NUMBER: 1991111109
TITLE: Effect of FGFs on adult bovine Muller cells: Proliferation, binding and internalization.
AUTHOR: Mascarelli F.; Tassin J.; Courtois Y.
CORPORATE SOURCE: INSERM U 118-CNRS UA 630, Association Claude Bernard, Unite de Recherches Gerontologiques, 29 Rue Wilhem, 75016 Paris, France
SOURCE: Growth Factors, (1991) 4/2 (81-95).
ISSN: 0897-7194 CODEN: GRFAEC
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 021 Developmental Biology and Teratology
029 Clinical Biochemistry
037 Drug Literature Index
LANGUAGE: English

SUMMARY LANGUAGE: English

AB A new method for culturing retinal Muller cells from adult **bovine** tissue is described. The identification of these glial cells was based on immunocytochemical analysis of specific Muller cell markers. Cultured cells from fourth to ninth passage showed positive labelling for S 100 protein, carbonic anhydrase (CAA), glutamine synthetase (GS), . **alpha. crystallin** (.alpha.C) and polyclonal glial fibrillary acidic protein (GFAP) antibody, but were negative for both monoclonal GFAP antibody and also for Muller cells in the retina. Investigation of the effect of acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and epithelial growth factor (EGF) on the proliferation of the Muller cells revealed that bFGF was the most potent mitogen (EC50 = 14 pM). Binding data revealed the presence of two classes of binding sites for aFGF and bFGF: (1) a high affinity binding site (Kd of 14 pM and 27 pM for aFGF and bFGF respectively); (2) a low affinity binding site (Kd of 3.2 nM and 0.6 nM for aFGF and bFGF respectively with great variability in the number of binding sites). In addition, the cross-linking experiments revealed the presence of high molecular weight FGF receptors (110-140 kDa). After aFGF or bFGF binding to Muller cells, aFGF and bFGF-cell surface receptors were rapidly downregulated with a half-life for disappearance of 35-50 min. Internalization and **degradation** of 125I-bFGF bound to the Muller cell receptors did not occur at 4.degree.C. At 37.degree.C, however, there was a rapid decrease in receptor-bound 125I-bFGF due to the downregulation of bFGF receptors. Concomitantly 125I-bFGF appeared inside the Muller cells. After 2 h, 125I-bFGF began to be degraded and after 6 h three fragments of 16 kDa, 8 kDa and 5.5 kDa were discernible. **Degradation** of bFGF appeared to occur in the lysosomal compartment since it was **inhibited** by chloroquine, an **inhibitor** of lysosomal **proteases**; aFGF internalization and **degradation** followed the same kinetics as bFGF with the appearance of 7 kDa and 5 kDa fragments. These results suggest that Muller cells may be the target for aFGF and bFGF contained in other cells of the retina. The fact that aFGF could be released from rod outer segment by a phosphorylation-dependent mechanism and that apical prolongation of the Muller cells is connected with the photoreceptor cells suggest that these factors may be the mediators involved in the communication between glial cells and neurons.

L72 ANSWER 18 OF 26 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
7

ACCESSION NUMBER: 1991:210162 BIOSIS
DOCUMENT NUMBER: BA91:113387
TITLE: CALPAIN IN CULTURED BOVINE LENS EPITHELIAL CELLS.
AUTHOR(S): LIPMAN R D; CYR D E; DAVID L L; TAYLOR A
CORPORATE SOURCE: LAB. NUTRITION VISION RES., USDA HUMAN NUTRITION RES. CENT.
AGING TUFTS UNIV., 711 WASHINGTON ST., BOSTON, MASS. 02111.
SOURCE: CURR EYE RES, (1991) 10 (1), 11-18.
CODEN: CEYRDM. ISSN: 0271-3683.
FILE SEGMENT: BA; OLD
LANGUAGE: English

AB Calcium dependent **proteolysis** was examined in supernatant prepared from cultured **bovine** lens epithelial (BLE) cells. The presence of the calcium activated **protease**, calpain, was indicated by immunorecognition of 80 kDa and 30 kDa subunits of calpain in BLE cell supernatant. **Degradation** of 125I-**alpha-crystallin** and FITC labeled casein by BLE cell supernatant were shown to be calcium dependent. **Inhibition** of activity was achieved with EGTA, calpastatin or CbzValPheH. The data presented are the first measurement of calpain activity in cultured lens cells.

L72 ANSWER 19 OF 26 MEDLINE
ACCESSION NUMBER: 90256007 MEDLINE
DOCUMENT NUMBER: 90256007 PubMed ID: 2341052
TITLE: Lens proteasome shows enhanced rates of **degradation**

of hydroxyl radical modified alpha-crystallin.

AUTHOR: Murakami K; Jahngen J H; Lin S W; Davies K J; Taylor A
 CORPORATE SOURCE: USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111.
 CONTRACT NUMBER: ES 03598 (NIEHS)
 SOURCE: FREE RADICAL BIOLOGY AND MEDICINE, (1990) 8 (3) 217-22.
 Journal code: 8709159. ISSN: 0891-5849.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199006
 ENTRY DATE: Entered STN: 19900720
 Last Updated on STN: 20000303
 Entered Medline: 19900628

AB Proteasome, a high molecular weight **protease** complex (HMP, approximately 600 kDa) was isolated from **bovine** eye lens epithelium tissue. In contrast with prior reports, lens proteasome degraded the major lens protein **alpha-crystallin** and S-carboxymethylated **bovine** serum albumin at 37 degrees C, mostly to trichloroacetic acid precipitable polypeptides. The proteasome, thus isolated, was labile at 55 degrees C. As indicated by the ability of p-chloromercuribenzoate and N-ethylmaleimide to block activity, a thiol group is required for activity. **Alpha-crystallin** was oxidized by exposure to 60Co-irradiation under an atmosphere of N2O (1-50 kilorads). This dose delivered 0.1-5.7 mol of hydroxyl radicals per mol of crystallin. Irradiation resulted in increased heterogeneity, aggregation, and fragmentation of the crystallin preparation. The proteolytic susceptibility of **alpha-crystallin** to the lens HMP was enhanced by the irradiation in a dose-dependent manner up to 20 kilorads (.OH concentration up to 2.3 mol per mol of **alpha-crystallin**). When 50 kilorads (5.7 mol .OH per mol of **alpha-crystallin**) was used, there was extensive aggregation and no enhancement in **proteolysis** over the unirradiated sample. The data indicate that the lens HMP can degrade mildly photooxidized lens proteins, but proteins which are extensively damaged are not degraded and may accumulate. This may be related to cataract formation.

L72 ANSWER 20 OF 26 MEDLINE DUPLICATE 8

ACCESSION NUMBER: 85251602 MEDLINE
 DOCUMENT NUMBER: 85251602 PubMed ID: 3893422
 TITLE: Differential **inhibition** of two proteolytic activities in bovine lens neutral-proteinase preparations.
 AUTHOR: Wagner B J; Margolis J W; Abramovitz A S; Fu S C
 SOURCE: BIOCHEMICAL JOURNAL, (1985 Jun 1) 228 (2) 517-9.
 Journal code: 2984726R. ISSN: 0264-6021.
 PUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198508
 ENTRY DATE: Entered STN: 19900320
 Last Updated on STN: 20000303
 Entered Medline: 19850821

AB Hydrolysis of carbobenzoxy-Leu-Leu-Glu 2-naphthylamide by **bovine** lens neutral-proteinase preparations is not affected by the esterase **inhibitor** di-isopropyl fluorophosphate, whereas hydrolysis of carbobenzoxy-Gly-Gly-Leu p-nitroanilide is completely **inhibited**. Hydrolysis of **alpha-crystallin**, a lens structural protein, can be **inhibited** by only 50% after prolonged treatment with di-isopropyl fluorophosphate. These data suggest that the lens neutral-proteinase preparation contains at least two enzymes, one of which may be a serine proteinase. This may account, in part, for the previously observed complex response of the preparation to **inhibitors**.

L72 ANSWER 21 OF 26 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1985:338530 BIOSIS

DOCUMENT NUMBER: BA80:8522

TITLE: CALCIUM-DEPENDENT CYSTEINE PROTEINASE CALPAIN IN BOVINE LENS **DEGRADATION** OF LENS STRUCTURAL PROTEINS.

AUTHOR(S): YOSHIDA H; MURACHI T; TSUKAHARA I

CORPORATE SOURCE: DEP. OPHTHALMOL., FAC. MED., KYOTO UNIV., 53 SHOGOINKAWARA-CHO, SAKYO-KU, KYOTO 606, JPN.

SOURCE: ACTA SOC OPHTHALMOL JPN, (1985) 89 (1), 227-229.
CODEN: NGZAA6. ISSN: 0029-0203.

FILE SEGMENT: BA; OLD

LANGUAGE: Japanese

AB Several urea-soluble lens proteins are good substrates of Ca²⁺-dependent cysteine proteinase (calpain) [EC 3.4.22.77] in **bovine** lens. The calpain-catalyzed **proteolysis** at 1 mM Ca²⁺ occurred with the proteins ranging from 40-200 kDa [kilo Daltons] which included actin (MW 43,000) and vimentin (MW 57,000). The **proteolysis** was **inhibited** by EGTA [ethylene glycol bis(.beta.-aminoethyl ether) N,N,N',N'-tetracetic acid] monoiodoacetic acid, E-46c [L-trans-epoxysuccinyl-L-leucylamido (3-methyl) butane], leupeptin [acetyl-L-leucyl-L-leucyl-L-argininal] and calpastatin (an endogenous specific **inhibitor** of calpain). Since calpain proteolyzed **alpha.-crystallin**, calpain may play some role in in vivo **degradation** of various structural proteins in the lens.

L72 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 9

ACCESSION NUMBER: 1984:402891 CAPLUS

DOCUMENT NUMBER: 101:2891

TITLE: Limited **proteolysis** of **bovine** lens **alpha.-crystallin** by calpain, a calcium-dependent cysteine proteinase, isolated from the same tissue

AUTHOR(S): Yoshida, Haruko; Murachi, Takashi; Tsukahara, Isamu

CORPORATE SOURCE: Fac. Med., Kyoto Univ., Kyoto, 606, Japan

SOURCE: Biochim. Biophys. Acta (1984), 798(2), 252-9
CODEN: BBACAQ; ISSN: 0006-3002

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Calpain (EC 3.4.22.17) (I) was found in the cytosolic fraction of bovine lens and purified to apparent homogeneity. Purified I required 1 mM Ca²⁺ for full activation and was composed of 2 subunits of mol. wt. 80,000 and 29,000 as demonstrated by SDS-polyacrylamide gel electrophoresis. I, when activated by Ca²⁺, degraded both A- and B-chains of **alpha.-crystallin**, which were also isolated from **bovine** lens. SDS-gel electrophoresis of the digest revealed that the A-chain (mol. wt. = 19,500) was degraded to produce an 18-kilodalton (kDa) polypeptide fragment and the B-chain (mol. wt. = 22,500) to produce a 19.5-kDa polypeptide fragment. No further cleavage, occurred even on prolonged incubation or after the 2nd addn. of the enzyme, indicating the uniquely limited **proteolysis** of each chain protein. The existence of calpastatin, the endogenous **inhibitor** protein specific for I, was also demonstrated in bovine lens cytosol.

L72 ANSWER 23 OF 26 MEDLINE

ACCESSION NUMBER: 84108733 MEDLINE

DOCUMENT NUMBER: 84108733 PubMed ID: 6363110

TITLE: Isolation and characterization of a 25K serine proteinase from bovine lens cortex.

AUTHOR: Srivastava O P; Ortwerth B J

CONTRACT NUMBER: EY 02035 (NEI)

SOURCE: EXPERIMENTAL EYE RESEARCH, (1983 Dec) 37 (6) 597-612.
Journal code: 0370707. ISSN: 0014-4835.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198403
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 20000303
Entered Medline: 19840323

AB A lens serine proteinase with trypsin-like specificity has been purified to homogeneity. This is one of two serine proteinases associated with the **alpha-crystallin** fraction from **bovine** lens. The purification was accomplished by a combination of isoelectric precipitation, activation to release the proteinase, gel-filtration and affinity chromatography. The purified proteinase showed a single protein band of 25 000 daltons on SDS-PAGE. A single protein band was also seen on non-denaturing gels which correlated with the location of the proteinase activity. The proteinase had a pH optimum between 7.2 and 8.2, was stable between pH 5.8 and 8.6 but was unstable above 40 degrees C upon heating. The enzyme lacked any requirement for metal ions and hydrolyzed arginine, lysine and asparagine substrates. **alpha-Crystallin**, and especially the B-chain of alpha-crystalline, was rapidly hydrolyzed by the proteinase compared to other lens crystallins. Metallo- and cysteine-proteinase **inhibitors** had no effect upon the enzyme activity whereas three different serine-proteinase **inhibitors** completely abolished all activity. A number of protein and peptide trypsin **inhibitors** also completely **inhibited** the lens 25K serine proteinase.

L72 ANSWER 24 OF 26 MEDLINE

ACCESSION NUMBER: 83157892 MEDLINE
DOCUMENT NUMBER: 83157892 PubMed ID: 6403363
TITLE: Purification and properties of a protein from bovine lens which **inhibits** trypsin and two endogenous lens proteinases.
AUTHOR: Srivastava O P; Ortwerth B J
CONTRACT NUMBER: EY 02035 (NEI)
SOURCE: EXPERIMENTAL EYE RESEARCH, (1983 Mar) 36 (3) 363-79.
Journal code: 0370707. ISSN: 0014-4835.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198305
ENTRY DATE: Entered STN: 19900318
Last Updated on STN: 19970203
Entered Medline: 19830527

AB An **inhibitor** of trypsin-like proteinases was isolated from the water-soluble proteins of **bovine** lens cortex. The **inhibitor** was purified by four simple procedures: the separation of the **inhibitor** fraction by Agarose A-1.5 m gel filtration, extraction with 2.5% TCA at 70 degrees C, ammonium sulfate precipitation of the TCA-soluble proteins and a final separation by gel filtration chromatography. This preparation was found to be homogeneous by SDS-PAGE with an approximate subunit molecular weight of 5500 daltons. Gel filtration separated the ammonium sulfate precipitate into an inactive high-molecular-weight peak which eluted in the void volume, and two peaks of approximately 40 000 daltons and 10 000 daltons. Both low-molecular-weight peaks gave a single 5500 dalton band on SDS-PAGE, but only the 40 000 dalton peak was active when concentrated and assayed with **bovine** trypsin. These data suggest that the **inhibitor** is present in multimeric forms in solution, but only the octamer appears to be active. Antibodies prepared against the purified **inhibitor** showed a single precipitin line, while no reaction was seen with an **alpha-crystallin** antiserum. Upon storage in solution all of the **inhibitor** became converted into a high-molecular-weight form which was completely inactive. SDS-PAGE dissociated the **inhibitor** aggregate into a major 44 000 dalton band along with

several minor bands. Amino acid analysis showed that the purified **inhibitor** contains a very high content of hydrophobic residues. The lens **inhibitor** was effective in reducing the activity of trypsin, but complete **inhibition** was not seen even at high **inhibitor** levels. A rapid and complete **inhibition** was observed, however, with two endogenous trypsin-like proteinases isolated from the **alpha-crystallin** region.

L72 ANSWER 25 OF 26 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 77110432 EMBASE
DOCUMENT NUMBER: 1977110432
TITLE: Neutral proteinase activity in the human lens.
AUTHOR: Trayhurn P.; Van Heyningen R.
CORPORATE SOURCE: Nuffield Lab. Ophthalmol., Univ. Oxford, United Kingdom
SOURCE: Experimental Eye Research, (1976) 22/3 (251-257).
CODEN: EXERA6
DOCUMENT TYPE: Journal
FILE SEGMENT: 012 Ophthalmology
029 Clinical Biochemistry
LANGUAGE: English

AB Enzymes associated with protein breakdown have been investigated in the human lens. A neutral proteinase has been found with properties similar to the **bovine** lens enzyme (Blow, van Heyningen and Barrett, 1975). It is maximally active at pH 7.5, stable for many hours at 55.degree.C, activated by Mg2+ and Ca2+ and **inhibited** by EDTA. It is active against bulk human lens proteins and **bovine** lens **.alpha** **. crystallin** but has little or no activity against haemoglobin, azocasein or **bovine** plasma albumin. The neutral proteinase appears to be the main, or only, proteinase in the normal and cataractous human lens; we were unable to find the proteinase with maximal activity at pH 5.2 described by Swanson and Nichols (1971). Neither leucine aminopeptidase nor carboxypeptidase A activity could be detected in the human lens.

L72 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 10
ACCESSION NUMBER: 1975:27850 CAPLUS
DOCUMENT NUMBER: 82:27850
TITLE: Trypsin and chymotrypsin **inhibitory** capacity of human and **bovine .alpha.-crystallin**
AUTHOR(S): Gaudin, Julien; Stevens, Frits C.
CORPORATE SOURCE: Fac. Med., Univ. Manitoba, Winnipeg, Manitoba, Can.
SOURCE: FEBS Lett. (1974), 48(1), 72-5
CODEN: FEBLAL
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Crude homogenates from bovine and human cataractous lenses, were able to **inhibit** trypsin and, to a lesser extent, chymotrypsin. The **inhibitory** activity was assocd. with the **.alpha.-crystallin** fraction of the lens. Aggregates of urea-denatured **.alpha.-crystallin** or of its acidic (**.alpha.A1**, **.alpha.A2**) or basic (**.alpha.B1**, **.alpha.B2**) components **inhibited** trypsin at least 5-fold more strongly than did native **.alpha.-crystallin**. The **Chymotrypsin inhibitory** activity of **.alpha.-crystallin** was much weaker than its trypsin/**inhibitory** activity and could not be increased by urea treatment or sepn. into the component acidic and basic polypeptide chains.

=>

FILE 'HOME' ENTERED AT 13:46:32 ON 28 OCT 2002

=> index bioscience chemistry business meetings patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.63

0.63

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...'

ENTERED AT 13:48:11 ON 28 OCT 2002

120 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s soluble and (protease or proteolysis) and (bovine (w) alpha (w) crystallin)

20 FILES SEARCHED...

34 FILES SEARCHED...

52 FILES SEARCHED...

67 FILES SEARCHED...

86 FILES SEARCHED...

112 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 120 FILES SEARCHED IN STNINDEX

L1 QUE SOLUABLE AND (PROTEASE OR PROTEOLYSIS) AND (BOVINE (W) ALPHA (W) CRYSTALLIN)

=> file hits

CLUSTER 'HITS' IS NOT VALID HERE

SESSION CONTINUES IN INDEX FILES 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, DRUGUPDATES, EMBAL, EMBASE, ESBIODASE, FEDRIP, FOMAD, FOREGE, FROSTI, FSTA, GENBANK, HEALSAFE, IFIPAT, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NIOSHTIC, NTIS, OCEAN, PASCAL, PHAR, PHARMAML, PHIC, PHIN, PROMT, SCISEARCH, SYNTHLINE, TOXCENTER, USPATFULL, USPAT2, VETB, VETU, WPIDS, WPINDEX, ALUMINIUM, AQUIRE, BABS, CAOLD, CBNB, CERAB, COMPENDEX, COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, INSPEC, INSPHYS, INVESTEXT, IPA, METADEX, NAPRALERT, PAPERCHEM2, RAPRA, RUSSCI, TULSA, TULSA2, USAN, WELDASEARCH, WSCA, IMOBILITY, ABCD, EUROPEX, IMSPROFILES, MATBUS, NLDB, PHARMASEARCH, PIRA, PLASNEWS, COMPUAB, CONF, ELCOM, EVENTLINE, IMSDRUGCONF, ISMEC, POLLUAB, SOLIDSTATE, CASREACT, DPCI, ENCOMPPAT, ENCOMPPAT2, EUROPATFULL, INPADOC, JAPIO, PATDD, PATDPA, PATOSDE, PATOSEP, PATOSWO, PCTFULL'

=> s l1

21 FILES SEARCHED...

41 FILES SEARCHED...

61 FILES SEARCHED...

87 FILES SEARCHED...

118 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 120 FILES SEARCHED IN STNINDEX

L2 QUE L1

=> s soluble and (protease or proteolysis) and (bovine (w) alpha (w) crystallin)

20 FILES SEARCHED...

1 FILE IFIPAT

41 FILES SEARCHED...

1 FILE USPATFULL

60 FILES SEARCHED...

1 FILE WPIDS
1 FILE WPINDEX
79 FILES SEARCHED...
108 FILES SEARCHED...
1 FILE PCTFULL

5 FILES HAVE ONE OR MORE ANSWERS, 120 FILES SEARCHED IN STNINDEX

L3 QUE SOLUBLE AND (PROTEASE OR PROTEOLYSIS) AND (BOVINE (W) ALPHA (W) CRYST
ALLIN)

=> file hits

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.96

17.59

FILE 'IFIPAT' ENTERED AT 14:07:34 ON 28 OCT 2002

COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPATFULL' ENTERED AT 14:07:34 ON 28 OCT 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:07:34 ON 28 OCT 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'PCTFULL' ENTERED AT 14:07:34 ON 28 OCT 2002

COPYRIGHT (C) 2002 Univentio

=> s l3

L4 1 FILE IFIPAT

L5 1 FILE USPATFULL

L6 1 FILE WPIDS

L7 1 FILE PCTFULL

TOTAL FOR ALL FILES

L8 4 L3

=> d l8 1-4 ibib abs

L8 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2002 IFI

AN 10198679 IFIPAT;IFIUDB;IFICDB

TITLE: METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND
SOLUBILITY

INVENTOR(S): Sanders; Mitchell C., Leicester, MA, US

PATENT ASSIGNEE(S): Unassigned

AGENT: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA
ROAD, P.O. BOX 9133, CONCORD, MA 01742-9133, US

NUMBER

PK

DATE

PATENT INFORMATION:

US 2002142384

A1

20021003

APPLICATION INFORMATION:

US 2001-848780

20010503

NUMBER

DATE

FAMILY INFORMATION:

US 2000-201407P20000503 (Provisional)

US 2002142384

20021003

DOCUMENT TYPE:

Utility

Patent Application - First Publication

FILE SEGMENT:

CHEMICAL

APPLICATION

GOVERNMENT INTEREST:

(0001) Part of this invention was made with government support under GM59535-01

awarded by the National Institute of Health under the Small Business Innovative Research (SBIR) Program. The U.S. Government has certain rights in this invention.

NUMBER OF CLAIMS: 5 8 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 shows a plasmid map for the Vector System DNA construct.

FIG. 2 is a representation of a pre-column filter placed in series with a resolving column such as a gel filtration or an ion exchange column.

FIG. 3 is a digital image of an SDS PAGE gel showing purified BCpepsinogen.

FIG. 4 shows a digital image of a 12% SDS PAGE gel of p26 protein purified by nickel affinity chromatography resin. Because p26 is a multi-oligomer, it has a tendency to elute over several fractions, even when a sharp gradient is provided. Fractions identified using the SDS gel and containing p26 are dialyzed into Pipes magnesium buffer (20 mM Pipes pH 7.0, 1 mM MgCl₂).

Following dialysis the target protein was stored at -20 degrees C. and used in less than 1 week for kinetic assays and chromatography experiments.

FIG. 5A shows the chromatograph of purified alpha-crystallin.

FIG. 5B provides a digital image of an SDS PAGE gel of purified alpha-crystallin.

FIG. 6 provides a graph that shows the inhibition of elastase activity with alpha-crystallin. Elastase activity was measured using a para-nitroaniline substrate obtained from Calbiochem (La Jolla, Calif.). Assays were performed with a Benchmark microplate reader (Bio-Rad). Elastase was purchased from either Sigma or Calbiochem. In a 100 μ l assay 50 μ g of peptide substrate, 1 μ g of elastase, and 50-100 μ g of either uncoupled p26, alpha-crystallin conjugated sepharose, BSA conjugated sepharose, or buffer (negative control) was used.

FIG. 7 is a graph that illustrates the NaCl dependency of alphacrystallin in inhibiting elastase activity. One μ g of elastase was incubated with 5 μ l of alpha-crystallin conjugated sepharose in the presence of 0-200 mM NaCl. Increasing the NaCl concentration reduced the ability of alphacrystallin to inhibit elastase activity.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the PROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The **soluble** recombinant protein is purified using a fusion tag.

CLMN 5 8 Figure(s).

FIG. 1 shows a plasmid map for the Vector System DNA construct.

FIG. 2 is a representation of a pre-column filter placed in series with a resolving column such as a gel filtration or an ion exchange column.

FIG. 3 is a digital image of an SDS PAGE gel showing purified BCpepsinogen.

FIG. 4 shows a digital image of a 12% SDS PAGE gel of p26 protein purified by nickel affinity chromatography resin. Because p26 is a multi-oligomer, it has a tendency to elute over several fractions, even when a sharp gradient is provided. Fractions identified using the SDS gel and containing p26 are dialyzed into Pipes magnesium buffer (20 mM Pipes pH 7.0, 1 mM MgCl₂). Following dialysis the target protein was stored at -20 degrees C. and used in less than 1 week for kinetic assays and chromatography experiments.

FIG. 5A shows the chromatograph of purified alpha-crystallin.

FIG. 5B provides a digital image of an SDS PAGE gel of purified alpha-crystallin.

FIG. 6 provides a graph that shows the inhibition of elastase activity with alpha-crystallin. Elastase activity was measured using a para-nitroaniline substrate obtained from Calbiochem (La Jolla, Calif.). Assays were performed with a Benchmark microplate reader (Bio-Rad). Elastase was purchased from either Sigma or Calbiochem. In a 100 μ l assay 50 μ g of peptide substrate, 1 μ g of elastase, and 50-100 μ g of either uncoupled p26, alpha-crystallin conjugated sepharose, BSA

conjugated sepharose, or buffer (negative control) was used.
 FIG. 7 is a graph that illustrates the NaCl dependency of alphacrystallin in inhibiting elastase activity. One μ g of elastase was incubated with 5 μ l of alpha-crystallin conjugated sepharose in the presence of 0-200 mM NaCl. Increasing the NaCl concentration reduced the ability of alphacrystallin to inhibit elastase activity.

L8 ANSWER 2 OF 4 USPATFULL

ACCESSION NUMBER: 2002:258814 USPATFULL
 TITLE: Method and device for improving protein stability and solubility
 INVENTOR(S): Sanders, Mitchell C., Leicester, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142384	A1	20021003
APPLICATION INFO.:	US 2001-848780	A1	20010503 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201407P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the mutiple cloning site of the PROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac I.sub.q). The soluble recombinant protein is purified using a fusion tag.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 4 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2002-011413 [01] WPIDS
 DOC. NO. CPI: C2002-002972
 TITLE: Improving stability and/or solubility of proteins expressed in vivo or in vitro.
 DERWENT CLASS: B04 D16
 INVENTOR(S): SANDERS, M C
 PATENT ASSIGNEE(S): (EXPR-N) EXPRESSIVE CONSTRUCTS INC; (SAND-I) SANDERS M C
 COUNTRY COUNT: 95
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001083804	A2	20011108	(200201)*	EN	23
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ					
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD					
SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001061242	A	20011112	(200222)		
US 2002142384	A1	20021003	(200267)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001083804	A2	WO 2001-US14692	20010503
AU 2001061242	A	AU 2001-61242	20010503
US 2002142384	A1 Provisional	US 2000-201407P	20000503
		US 2001-848780	20010503

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001061242	A Based on	WO 200183804

PRIORITY APPLN. INFO: US 2000-201407P 20000503; US 2001-848780
20010503

AN 2002-011413 [01] WPIDS

AB WO 200183804 A UPAB: 20020105

NOVELTY - Methods for improving protein stability and/or solubility, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method (I) for producing a **soluble** and active recombinant protein comprising:

(a) inserting the p26 betas-core domain into a vector;
(b) inserting the insoluble protein domain into the vector directly after the p26 domain;
(c) inserting the vector into bacterial cells;
(d) growing the bacteria in a culture to an optical density (OD) of 0.8-1.0; and
(e) inducing the culture with IPTG;

(2) a method (II) for preventing unwanted **proteolysis** of a recombinant protein comprising:

(A) inserting **bovine alpha-crystallin** into a vector;

(B) inserting the protein of interest into a vector; and
(C) steps (c) to (e) from (I);

(3) a method for purifying native **bovine alpha-crystallin** protein comprising:

(a) homogenizing bovine eye lenses in a buffer;
(b) binding alpha-crystallin protein to a Q column;
(c) eluting the alpha-crystallin with a high salt; and
(d) separating the protein in 100 mM Glycine pH 2.5 on a Macrorep (RTM) column;

(4) a method of purifying recombinant alpha-crystallin type HIS-tagged proteins comprising:

(a) inserting the alpha-crystallin protein domain into a vector with the hexa-his tag;

(b) inserting the vector into bacterial cells and growing/inducing the cells;

(c) lyzing the cells and centrifuging out cell debris; and

(d) purifying the alpha-crystallin protein using an Ni-NTA column; and

(5) a method (V) for protecting a protein from **proteolysis** during purification, comprising:

(A) coupling purified **bovine alpha-crystallin** protein to a chromatography resin (CNBr-activated Sepharose (RTM) 4B or NHS-activated Sepharose 4B);

(B) rinsing and blocking the resin with BSA; and

(C) using the resin to purify the protein of choice.

USE - The methods are used to improve protein stability, folding and/or solubility when produced either in vivo or in vitro.

Dwg.0/7

ACCESSION NUMBER: 2001083804 PCTFULL ED 20020826
 TITLE (ENGLISH): A METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND SOLUBILITY
 TITLE (FRENCH): METHODE ET DISPOSITIF POUR AMELIORER LA STABILITE ET LA SOLUBILITE DE PROTEINES
 INVENTOR(S): SANDERS, Mitchell, C.
 PATENT ASSIGNEE(S): EXPRESSIVE CONSTRUCTS, INC.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001083804	A2	20011108
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		

APPLICATION INFO.: WO 2001-US14692 A 20010503
 PRIORITY INFO.: US 2000-60/201,407 20000503

ABEN A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as *E. Coli* is provided. Genes of interest are cloned into the multiple cloning site of the pPROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1mMIPTG that overcomes the lac repression (lac Iq). The **soluble** recombinant protein is purified using a fusion tag.

ABFR L'invention concerne une methode servant a exprimer des proteines en tant que chimere de fusion presentant un domaine proteique de type p26 ou alpha-crystallin, destinee a ameliorer la stabilite et la solubilite des proteines lorsqu'elles sont exprimees excessivement dans des bacteries telles que *E. Coli*. Des genes d'interet sont clones dans le site de clonage multiple du systeme vectorette pPROTECT juste en aval de la proteine de type p26 ou alpha-crystallin et d'un site de clivage de thrombine. L'expression proteique est effectuee par un puissant promoteur bacterien (TAC). Cette expression est induite par l'addition de 1mMIPTG qui surmonte la repression de lac (lac Iq). La proteine recombinante **soluble** est purifiee au moyen d'un fragment de fusion.

FILE 'HOME' ENTERED AT 14:44:56 ON 28 OCT 2002

=> index bioscience agriculture patents meetings businessresaerch

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

'BUSINESSRESA' IS NOT A VALID FILE NAME

ENTER A FILE NAME OR (IGNORE):business resaerch

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

'RESAERCH' IS NOT A VALID FILE NAME

ENTER A FILE NAME OR (IGNORE):research

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.84	0.84

FULL ESTIMATED COST

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...'

ENTERED AT 14:47:01 ON 28 OCT 2002

110 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s soluble and (proteolysis or degradation or proteolysed) and (bovine (w) alpha (w)
crystallin)

20 FILES SEARCHED...

37 FILES SEARCHED...

1 FILE IFIPAT

54 FILES SEARCHED...

1 FILE USPATFULL

1 FILE WPIDS

1 FILE WPINDEX

68 FILES SEARCHED...

1 FILE PCTFULL

88 FILES SEARCHED...

5 FILES HAVE ONE OR MORE ANSWERS, 110 FILES SEARCHED IN STNINDEX

L1 QUE SOLUBLE AND (PROTEOLYSIS OR DEGRADATION OR PROTEOLYSED) AND (BOVINE (W
) ALPHA (W) CRYSTALLIN)

=> file hits

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.30	6.14

FULL ESTIMATED COST

FILE 'IFIPAT' ENTERED AT 14:52:46 ON 28 OCT 2002

COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPATFULL' ENTERED AT 14:52:46 ON 28 OCT 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:52:46 ON 28 OCT 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'PCTFULL' ENTERED AT 14:52:46 ON 28 OCT 2002

COPYRIGHT (C) 2002 Univentio

=> s l1

L2 1 FILE IFIPAT

L3 1 FILE USPATFULL

L4 1 FILE WPIDS

L5 1 FILE PCTFULL

TOTAL FOR ALL FILES

L6 4 L1

=> d 16 1-4 ibib abs

L6 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2002 IFI

AN 10198679 IFIPAT;IFIUDB;IFICDB

TITLE: METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND SOLUBILITY

INVENTOR(S): Sanders; Mitchell C., Leicester, MA, US

PATENT ASSIGNEE(S): Unassigned

AGENT: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA 01742-9133, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002142384	A1	20021003
APPLICATION INFORMATION:	US 2001-848780		20010503

	NUMBER	DATE
	US 2000-201407P20000503	(Provisional)
FAMILY INFORMATION:	US 2002142384	20021003
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	

GOVERNMENT INTEREST:

(0001) Part of this invention was made with government support under GM59535-01 awarded by the National Institute of Health under the Small Business Innovative Research (SBIR) Program. The U.S. Government has certain rights in this invention.

NUMBER OF CLAIMS: 5 8 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 shows a plasmid map for the Vector System DNA construct.

FIG. 2 is a representation of a pre-column filter placed in series with a resolving column such as a gel filtration or an ion exchange column.

FIG. 3 is a digital image of an SDS PAGE gel showing purified BCpepsinogen.

FIG. 4 shows a digital image of a 12% SDS PAGE gel of p26 protein purified by nickel affinity chromatography resin. Because p26 is a multi-oligomer, it has a tendency to elute over several fractions, even when a sharp gradient is provided. Fractions identified using the SDS gel and containing p26 are dialyzed into Pipes magnesium buffer (20 mM Pipes pH 7.0, 1 mM MgCl₂). Following dialysis the target protein was stored at -20 degrees C. and used in less than 1 week for kinetic assays and chromatography experiments.

FIG. 5A shows the chromatograph of purified alpha-crystallin.

FIG. 5B provides a digital image of an SDS PAGE gel of purified alpha-crystallin.

FIG. 6 provides a graph that shows the inhibition of elastase activity with alpha-crystallin. Elastase activity was measured using a para-nitroaniline substrate obtained from Calbiochem (La Jolla, Calif.). Assays were performed with a Benchmark microplate reader (Bio-Rad). Elastase was purchased from either Sigma or Calbiochem. In a 100 mu l assay 50 mu g of peptide substrate, 1 mu g of elastase, and 50-100 mu g of either uncoupled p26, alpha-crystallin conjugated sepharose, BSA conjugated sepharose, or buffer (negative control) was used.

FIG. 7 is a graph that illustrates the NaCl dependency of alphacrystallin in inhibiting elastase activity. One mu g of elastase was incubated with 5 mu l of alpha-crystallin conjugated sepharose in the presence of 0-200 mM NaCl. Increasing the NaCl concentration reduced the ability of alphacrystallin to inhibit elastase activity.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the mutiple cloning site of the pROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The **soluble** recombinant protein is purified using a fusion tag.

CLMN 5 8 Figure(s).

FIG. 1 shows a plasmid map for the Vector System DNA construct.

FIG. 2 is a representation of a pre-column filter placed in series with a resolving column such as a gel filtration or an ion exchange column.

FIG. 3 is a digital image of an SDS PAGE gel showing purified BCpepsinogen.

FIG. 4 shows a digital image of a 12% SDS PAGE gel of p26 protein purified by nickel affinity chromatography resin. Because p26 is a multi-oligomer, it has a tendency to elute over several fractions, even when a sharp gradient is provided. Fractions identified using the SDS gel and containing p26 are dialyzed into Pipes magnesium buffer (20 mM Pipes pH 7.0, 1 mM MgCl₂). Following dialysis the target protein was stored at -20 degrees C. and used in less than 1 week for kinetic assays and chromatography experiments.

FIG. 5A shows the chromatograph of purified alpha-crystallin.

FIG. 5B provides a digital image of an SDS PAGE gel of purified alpha-crystallin.

FIG. 6 provides a graph that shows the inhibition of elastase activity with alpha-crystallin. Elastase activity was measured using a para-nitroaniline substrate obtained from Calbiochem (La Jolla, Calif.). Assays were performed with a Benchmark microplate reader (Bio-Rad). Elastase was purchased from either Sigma or Calbiochem. In a 100 mu l assay 50 mu g of peptide substrate, 1 mu g of elastase, and 50-100 mu g of either uncoupled p26, alpha-crystallin conjugated sepharose, BSA conjugated sepharose, or buffer (negative control) was used.

FIG. 7 is a graph that illustrates the NaCl dependency of alphacrystallin in inhibiting elastase activity. One mu g of elastase was incubated with 5 mu l of alpha-crystallin conjugated sepharose in the presence of 0-200 mM NaCl. Increasing the NaCl concentration reduced the ability of alphacrystallin to inhibit elastase activity.

L6 ANSWER 2 OF 4 USPATFULL

ACCESSION NUMBER: 2002:258814 USPATFULL

TITLE: Method and device for improving protein stability and solubility

INVENTOR(S): Sanders, Mitchell C., Leicester, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142384	A1	20021003
APPLICATION INFO.:	US 2001-848780	A1	20010503 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201407P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability

and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the mutiple cloning site of the pPROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac I.sub.q). The **soluble** recombinant protein is purified using a fusion tag.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 4 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2002-011413 [01] WPIDS

DOC. NO. CPI: C2002-002972

TITLE: Improving stability and/or solubility of proteins expressed in vivo or in vitro.

DERWENT CLASS: B04 D16

INVENTOR(S): SANDERS, M C

PATENT ASSIGNEE(S): (EXPR-N) EXPRESSIVE CONSTRUCTS INC; (SAND-I) SANDERS M C

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001083804	A2	20011108	(200201)*	EN	23
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ					
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD					
SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001061242	A	20011112	(200222)		
US 2002142384	A1	20021003	(200267)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001083804	A2	WO 2001-US14692	20010503
AU 2001061242	A	AU 2001-61242	20010503
US 2002142384	A1 Provisional	US 2000-201407P	20000503
		US 2001-848780	20010503

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001061242	A Based on	WO 200183804

PRIORITY APPLN. INFO: US 2000-201407P 20000503; US 2001-848780 20010503

AN 2002-011413 [01] WPIDS

AB WO 200183804 A UPAB: 20020105

NOVELTY - Methods for improving protein stability and/or solubility, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method (I) for producing a **soluble** and active recombinant protein comprising:

- (a) inserting the p26 betas-core domain into a vector;
- (b) inserting the insoluble protein domain into the vector directly after the p26 domain;
- (c) inserting the vector into bacterial cells;
- (d) growing the bacteria in a culture to an optical density (OD) of 0.8-1.0; and

(e) inducing the culture with IPTG;
 (2) a method (II) for preventing unwanted **proteolysis** of a recombinant protein comprising:
 (A) inserting **bovine alpha-crystallin** into a vector;
 (B) inserting the protein of interest into a vector; and
 (C) steps (c) to (e) from (I);
 (3) a method for purifying native **bovine alpha-crystallin** protein comprising:
 (a) homogenizing bovine eye lenses in a buffer;
 (b) binding alpha-crystallin protein to a Q column;
 (c) eluting the alpha-crystallin with a high salt; and
 (d) separating the protein in 100 mM Glycine pH 2.5 on a Macrorep (RTM) column;
 (4) a method of purifying recombinant alpha-crystallin type HIS-tagged proteins comprising:
 (a) inserting the alpha-crystallin protein domain into a vector with the hexa-his tag;
 (b) inserting the vector into bacterial cells and growing/inducing the cells;
 (c) lyzing the cells and centrifuging out cell debris; and
 (d) purifying the alpha-crystallin protein using an Ni-NTA column;
 and
 (5) a method (V) for protecting a protein from **proteolysis** during purification, comprising:
 (A) coupling purified **bovine alpha-crystallin** protein to a chromatography resin (CNBr-activated Sepharose (RTM) 4B or NHS-activated Sepharose 4B);
 (B) rinsing and blocking the resin with BSA; and
 (C) using the resin to purify the protein of choice.
 USE - The methods are used to improve protein stability, folding and/or solubility when produced either in vivo or in vitro.
 Dwg.0/7

L6 ANSWER 4 OF 4 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2001083804 PCTFULL ED 20020826
 TITLE (ENGLISH): A METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND SOLUBILITY
 TITLE (FRENCH): METHODE ET DISPOSITIF POUR AMELIORER LA STABILITE ET LA SOLUBILITE DE PROTEINES
 INVENTOR(S): SANDERS, Mitchell, C.
 PATENT ASSIGNEE(S): EXPRESSIVE CONSTRUCTS, INC.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001083804	A2	20011108
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US14692	A	20010503
PRIORITY INFO.:	US 2000-60/201,407		20000503

ABEN A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as *E. Coli* is provided. Genes of interest are cloned into the multiple cloning site of the pPROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1mMIPTG that overcomes the lac repression (lac Iq). The

soluble recombinant protein is purified using a fusion tag.

ABFR L'invention concerne une methode servant a exprimer des proteines en tant que chimere de fusion presentant un domaine proteique de type p26 ou alpha-crystallin, destinee a ameliorer la stabilite et la solubilite des proteines lorsqu'elles sont exprimees excessivement dans des bacteries telles que *E. Coli*. Des genes d'interet sont clones dans le site de clonage multiple du systeme vectorette PROTECT juste en aval de la proteine de type p26 ou alpha-crystallin et d'un site de clivage de thrombine. L'expression proteique est effectuee par un puissant promoteur bacterien (TAC). Cette expression est induite par l'addition de 1mMIPTG qui surmonte la repression de lac (lac Iq). La proteine recombinante **soluble** est purifiee au moyen d'un fragment de fusion.

=> s soluble and (proteolysis or degradation or proteolysed) and (alpha (w) crystallin)

L7 1 FILE IFIPAT
L8 34 FILE USPATFULL
L9 1 FILE WPIDS
L10 12 FILE PCTFULL

TOTAL FOR ALL FILES

L11 48 SOLUBLE AND (PROTEOLYSIS OR DEGRADATION OR PROTEOLYSED) AND
(ALPHA (W) CRYSTALLIN)

=> dup rem l11

PROCESSING COMPLETED FOR L11

L12 46 DUP REM L11 (2 DUPLICATES REMOVED)

=> d l12 1-46 ibib abs

L12 ANSWER 1 OF 46 IFIPAT COPYRIGHT 2002 IFI DUPLICATE 1

AN 10198679 IFIPAT;IFIUDB;IFICDB

TITLE: METHOD AND DEVICE FOR IMPROVING PROTEIN STABILITY AND SOLUBILITY

INVENTOR(S): Sanders; Mitchell C., Leicester, MA, US

PATENT ASSIGNEE(S): Unassigned

AGENT: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA 01742-9133, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002142384	A1	20021003
APPLICATION INFORMATION:	US 2001-848780		20010503

	NUMBER	DATE
	US 2000-201407P20000503	(Provisional)
FAMILY INFORMATION:	US 2002142384	20021003
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	

GOVERNMENT INTEREST:

(0001) Part of this invention was made with government support under GM59535-01 awarded by the National Institute of Health under the Small Business Innovative Research (SBIR) Program. The U.S. Government has certain rights in this invention.

NUMBER OF CLAIMS: 5 8 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 shows a plasmid map for the Vector System DNA construct.

FIG. 2 is a representation of a pre-column filter placed in series with a resolving column such as a gel filtration or an ion exchange column.

FIG. 3 is a digital image of an SDS PAGE gel showing purified BCpepsinogen. FIG. 4 shows a digital image of a 12% SDS PAGE gel of p26 protein purified by nickel affinity chromatography resin. Because p26 is a multi-oligomer, it has a tendency to elute over several fractions, even when a sharp gradient is provided. Fractions identified using the SDS gel and containing p26 are dialyzed into Pipes magnesium buffer (20 mM Pipes pH 7.0, 1 mM MgCl₂). Following dialysis the target protein was stored at -20 degrees C. and used in less than 1 week for kinetic assays and chromatography experiments. FIG. 5A shows the chromatograph of purified **alpha-crystallin**

FIG. 5B provides a digital image of an SDS PAGE gel of purified **alpha-crystallin**.

FIG. 6 provides a graph that shows the inhibition of elastase activity with *****alpha*** -crystallin**. Elastase activity was measured using a para-nitroaniline substrate obtained from Calbiochem (La Jolla, Calif.). Assays were performed with a Benchmark microplate reader (Bio-Rad). Elastase was purchased from either Sigma or Calbiochem. In a 100 μ l assay 50 μ g of peptide substrate, 1 μ g of elastase, and 50-100 μ g of either uncoupled p26, *****alpha*** -crystallin** conjugated sepharose, BSA conjugated sepharose, or buffer (negative control) was used.

FIG. 7 is a graph that illustrates the NaCl dependency of alphacrystallin in inhibiting elastase activity. One μ g of elastase was incubated with 5 μ l of *****alpha*** -crystallin** conjugated sepharose in the presence of 0-200 mM NaCl. Increasing the NaCl concentration reduced the ability of alphacrystallin to inhibit elastase activity.

AB A method for expressing proteins as a fusion chimera with a domain of p26 or **alpha crystallin** type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the pROTECT Vector System just downstream of the p26 or **alpha crystallin** type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The **soluble** recombinant protein is purified using a fusion tag.

CLMN 5 8 Figure(s).

FIG. 1 shows a plasmid map for the Vector System DNA construct.

FIG. 2 is a representation of a pre-column filter placed in series with a resolving column such as a gel filtration or an ion exchange column.

FIG. 3 is a digital image of an SDS PAGE gel showing purified BCpepsinogen.

FIG. 4 shows a digital image of a 12% SDS PAGE gel of p26 protein purified by nickel affinity chromatography resin. Because p26 is a multi-oligomer, it has a tendency to elute over several fractions, even when a sharp gradient is provided. Fractions identified using the SDS gel and containing p26 are dialyzed into Pipes magnesium buffer (20 mM Pipes pH 7.0, 1 mM MgCl₂). Following dialysis the target protein was stored at -20 degrees C. and used in less than 1 week for kinetic assays and chromatography experiments.

FIG. 5A shows the chromatograph of purified **alpha-crystallin**.

FIG. 5B provides a digital image of an SDS PAGE gel of purified **alpha-crystallin**.

FIG. 6 provides a graph that shows the inhibition of elastase activity with **alpha-crystallin**. Elastase activity was measured using a para-nitroaniline substrate obtained from Calbiochem (La Jolla, Calif.). Assays were performed with a Benchmark microplate reader (Bio-Rad). Elastase was purchased from either Sigma or Calbiochem. In a 100 μ l assay 50 μ g of peptide substrate, 1 μ g of elastase, and 50-100 μ g of either uncoupled p26, **alpha-crystallin** conjugated sepharose, BSA conjugated sepharose, or buffer (negative control) was used.

FIG. 7 is a graph that illustrates the NaCl dependency of alphacrystallin in inhibiting elastase activity. One μ g of elastase was incubated with 5 μ l of **alpha-crystallin** conjugated sepharose in

the presence of 0-200 mM NaCl. Increasing the NaCl concentration reduced the ability of alphacrystallin to inhibit elastase activity.

L12 ANSWER 2 OF 46 USPATFULL

ACCESSION NUMBER: 2002:280000 USPATFULL
TITLE: Hepatitis B virus treatment
INVENTOR(S): Mizzen, Lee A., Victoria, CANADA
Siegel, Marvin, Blue Bell, PA, UNITED STATES
Liu, Hongwei, Victoria, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002155434	A1	20021024
APPLICATION INFO.:	US 2002-68059	A1	20020205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266733P	20010205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LEE CREWS, PH.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	1452	

AB The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.

L12 ANSWER 3 OF 46 USPATFULL

ACCESSION NUMBER: 2002:243567 USPATFULL
TITLE: Method for identifying compounds to treat medical pathologies associated with molecular crystallization
INVENTOR(S): Shell, John W., Hillsborough, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132758	A1	20020919
APPLICATION INFO.:	US 2002-52712	A1	20020117 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262987P	20010118 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	114	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1620	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Numerous diseases and disorders are caused or exacerbated by the formation of crystalline aggregates of a biomolecule that is normally in solution. Such diseases and disorders include cataracts, sickle cell anemia, atherosclerosis, kidney stones, gallstones, gout, and Alzheimer's disease. The present invention provides methods to identify compounds that can inhibit the adverse formation of crystalline aggregates, including fibrils, of a target biomolecule. These methods include the screening of large combinatorial libraries. The identified compounds are tested for their therapeutic utility in treating medical conditions caused or exacerbated by the adverse crystallization of

biomolecules. Molecules that are slight modifications of the target biomolecule are found to be particularly effective in inhibiting the adverse crystallization, including fibril formation, of a target biomolecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 46 USPATFULL

ACCESSION NUMBER: 2002:221323 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna L., Mount Airy, MD, UNITED STATES
Porter, Mark W., Germantown, MD, UNITED STATES
Johnson, Kory R., Bethesda, MD, UNITED STATES
Castle, Arthur L., Washington, DC, UNITED STATES
Elashoff, Michael R., Germantown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119462	A1	20020829
APPLICATION INFO.:	US 2001-917800	A1	20010731 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-222040P	20000731 (60)
	US 2000-244880P	20001102 (60)
	US 2001-290029P	20010511 (60)
	US 2001-290645P	20010515 (60)
	US 2001-292336P	20010522 (60)
	US 2001-295798P	20010606 (60)
	US 2001-297457P	20010613 (60)
	US 2001-298884P	20010619 (60)
	US 2001-303459P	20010709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE
NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 9801

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 46 USPATFULL

ACCESSION NUMBER: 2002:205879 USPATFULL
TITLE: Human papilloma virus treatment
INVENTOR(S): Neefe, John R., Devon, PA, UNITED STATES
Goldstone, Stephen E., New York, NY, UNITED STATES
Winnett, Mark T., Phoenixville, PA, UNITED STATES
Siegel, Marvin, Blue Bell, PA, UNITED STATES
Boux, Leslie J., Victoria, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110566	A1	20020815
APPLICATION INFO.:	US 2001-891823	A1	20010626 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2000-214202P 20000626 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LEE CREWS, PH. D., Fish & Richardson P.C., 225 Franklin
Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 1257

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 46 USPATFULL

ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102604	A1	20020801
APPLICATION INFO.:	US 2000-731872	A1	20001207 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John Lucas, Ph.D., J.D., Genset Corporation, 10665 Sorrento Valley Road, San Diego, CA, 92121-1609	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	28061	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 46 USPATFULL

ACCESSION NUMBER: 2002:178550 USPATFULL
TITLE: Nucleic acid fragments and polypeptide fragments
derived from M. tuberculosis
INVENTOR(S): Andersen, Peter, Bronshoj, DENMARK
Nielsen, Rikke, Frederiksberg C, DENMARK
Oettinger, Thomas, Hellerup, DENMARK

PATENT ASSIGNEE(S): Rasmussen, Peter Birk, Kobenhaven O, DENMARK
 Rosenkrands, Ida, Kobenhaven O, DENMARK
 Weldingh, Karin, Kobenhaven N, DENMARK
 Florio, Walter, Frederiksberg C, DENMARK
 STATENS SERUM INSTITUT (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094336	A1	20020718
APPLICATION INFO.:	US 2001-791171	A1	20010220 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-50739, filed on 30 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1997-376	19970402
	DK 1997-1277	19971110
	US 1997-44624P	19970418 (60)
	US 1998-70488P	19980105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FROMMER LAWRENCE & HAUG LLP, 745 FIFTH AVENUE, NEW YORK, NY, 10151	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	6134	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 46 USPATFULL

ACCESSION NUMBER: 2002:157089 USPATFULL
 TITLE: Retinoid pathway assays, and compositions therefrom
 INVENTOR(S): Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
 Richards, Burt Timothy, Midway, UT, UNITED STATES
 Karpilow, Jon, Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081688	A1	20020627
APPLICATION INFO.:	US 2001-990747	A1	20011116 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-812994, filed on 4 Mar 1997, GRANTED, Pat. No. US 5955275		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249468P	20001117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Joseph A. Williams, Jr., MARSHALL, GERSTEIN, MURRAY & BORUN, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL, 60606-6402	
NUMBER OF CLAIMS:	110	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Page(s)
LINE COUNT: 3714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for assaying a cellular pathway, and more particularly a retinoic acid-related pathway, are disclosed. The assays of the invention utilize particular host cells with desired retinoic acid pathway elements, and results in the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 46 USPATFULL

ACCESSION NUMBER: 2002:16850 USPATFULL
TITLE: Human stress array
INVENTOR(S): Chenchik, Alex, Palo Alto, CA, UNITED STATES
Lukashev, Matvey E., Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009730	A1	20020124
APPLICATION INFO.:	US 2001-782909	A1	20010213 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-441920, filed on 17 Nov 1999, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Bret E. Field, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA, 94025		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2377		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 46 USPATFULL

ACCESSION NUMBER: 2002:8197 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., Lexington, MA, UNITED STATES
Nyanguile, Origene, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004195	A1	20020110
APPLICATION INFO.:	US 2000-751309	A1	20001229 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-208057, filed on 9 Dec 1998, GRANTED, Pat. No. US 6183965 Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997, GRANTED, Pat. No. US 6153383		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		

LINE COUNT: 3196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 46 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002081731 PCTFULL ED 20021028 EW 200242
TITLE (ENGLISH): NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
TITLE (FRENCH): NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES
INVENTOR(S): TANG, Tom, Y.; LIU, Chenghua; ZHOU, Ping; ASUNDI, Vinod; ZHANG, Jie; ZHAO, Qing, A.; REN, Feiyan; XUE, Aidong, J.; YANG, Yonghong; WEHRMAN, Tom; WANG, Jian-Rui; WANG, Dunrui; DRMANAC, Radoje, T.
PATENT ASSIGNEE(S): HYSEQ, INC., for all designates States except US; GOODRICH, Ryle, W., for US only; TANG, Tom, Y., for US only; LIU, Chenghua, for US only; ZHOU, Ping, for US only; ASUNDI, Vinod, for US only; ZHANG, Jie, for US only; ZHAO, Qing, A., for US only; REN, Feiyan, for US only; XUE, Aidong, J., for US only; YANG, Yonghong, for US only; WEHRMAN, Tom, for US only; WANG, Jian-Rui, for US only; WANG, Dunrui, for US only; DRMANAC, Radoje, T., for US only
AGENT: HSI, Petrina, S.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002081731	A2	20021017
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US1222	A	20020129
PRIORITY INFO.:	US 2001-09/774,528		20010130

ABEN The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.
ABFR La presente invention concerne de nouveaux acides nucleiques, de nouvelles sequences polypeptidiques codees par ces acides nucleiques, et leurs utilisations.

L12 ANSWER 12 OF 46 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002070647 PCTFULL ED 20020926 EW 200237
TITLE (ENGLISH): DENATURAT STABLE AND/OR PROTEASE RESISTANT, CHAPERONE-LIKE OLIGOMERIC PROTEINS, POLYNUCLEOTIDES ENCODING SAME AND THEIR USES
TITLE (FRENCH): PROTEINES OLIGOMERES SEMBLABLES A UNE CHAPERONE, STABLES FACE AUX DENATURANTS ET/OU RESISTANT A LA PROTEASE, POLYNUCLEOTIDES CODANT LES MEMES PROTEINES ET UTILISATIONS CORRESPONDANTES
INVENTOR(S): WANG, Wangxia; PELAH, Dan; ALEGRAND, Tal; SHOSEYOV, Oded; ALTMAN, Arie
PATENT ASSIGNEE(S): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, for all designates States

AGENT: except US; WANG, Wangxia, for US only; PELAH, Dan, for
 LANGUAGE OF FILING: US only; ALEGRAND, Tal, for US only; SHOSEYOV, Oded,
 LANGUAGE OF PUBL.: for US only; ALTMAN, Arie, for US only
 DOCUMENT TYPE: G. E. EHRLICH (1995) LTD.
 PATENT INFORMATION: English
 English
 Patent

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2002070647	A2	20020912
	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO		
	CR CU CZ DE DK DM DZ EC EE EE ES FI FI GB GD		
	GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR		
	LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT		
	RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US		
	UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM		
	ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI		
	FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA		
	GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-IL174	A	20020305
PRIORITY INFO.:	US 2001-60/272,771		20010305

ABEN Novel denaturant-stable, protease resistant, homo-oligomeric proteins, also referred to herein as stable proteins (SPs), having chaperone-like activity; methods of production and purification of SPs; nucleic acids encoding SPs; methods of isolating nucleic acids encoding SPs; antibodies recognizing SPs; the use of SPs for stabilizing, refolding, repairing, preventing aggregation and de-aggregating macromolecules such as proteins; fusion proteins including SPs; nucleic acid constructs encoding the fusion proteins; and their uses in a variety of methods and applications.

ABFR L'invention se rapporte a de nouvelles proteines homo-oligomeriques, resistant a la protease et stables face aux denaturants, egalement appeles proteines stables (SP) et dont l'activite est semblable a celle de la chaperone ; a des procedes de fabrication et de purification des SP ; a des acides nucleiques codant les SP ; a des procedes d'isolation d'acides nucleiques codant les SP ; a des anticorps reconnaissant les SP ; a l'utilisation de SP afin de stabiliser, replier, reparer empecher l'agregation et la desagregation de macromolecules telles que les proteines ; a des proteines de fusion comprenant les SP ; a des constructions d'acide nucleique codant les proteines de fusion ; et a leur utilisation dans differents procedes et differentes applications.

L12 ANSWER 13 OF 46 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2002062959 PCTFULL ED 20020827 EW 200233
 TITLE (ENGLISH): HEPATITIS B VIRUS TREATMENT
 TITLE (FRENCH): TRAITEMENT DU VIRUS DE L'HEPATITE B
 INVENTOR(S): MIZZEN, Lee; LIU, Hongwei; SIEGEL, Marvin
 PATENT ASSIGNEE(S): STRESSGEN BIOTECHNOLOGIES CORP., for all designates
 States except US; MIZZEN, Lee, for US only; LIU,
 Hongwei, for US only; SIEGEL, Marvin, for US only
 FRASER, Janis, K.

AGENT: English
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: Patent
 DOCUMENT TYPE:
 PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2002062959	A2	20020815
	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR		
	CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID		
	IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD		
	MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI		
	SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH		
	GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD		

RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN
TD TG

APPLICATION INFO.: WO 2002-US3460 A 20020205
PRIORITY INFO.: US 2001-60/266,733 20010205

ABEN The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (<i>e.g.</i>, a fragment) or derivative thereof, and an HBV antigen.

ABFR L'invention concerne des compositions contenant un antigene du virus de l'hepatite B (HBV) utilisees pour traiter ou prevenir une infection induite par le HBV. Le contenu des compositions peut varier, et ces compositions comprennent une proteine de stress, ou une partie (par exemple, un fragment) ou un derive de celle-ci, et un antigene contre le HBV.

L12 ANSWER 14 OF 46 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002057796 PCTFULL ED 20020801 EW 200230
TITLE (ENGLISH): METHOD FOR IDENTIFYING COMPOUNDS TO TREAT MEDICAL
PATHOLOGIES ASSOCIATED WITH MOLECULAR CRYSTALLIZATION
TITLE (FRENCH): PROCEDE D'IDENTIFICATION DE COMPOSES POUR TRAITER DES
PATHOLOGIES ASSOCIEES A LA CRISTALLISATION MOLECULAIRE
INVENTOR(S): SHELL, John, W.
PATENT ASSIGNEE(S): SHELL, John, W.
AGENT: REED, Dianne, E.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

DESIGNATED STATES WO 2002057796 A2 20020725
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW GH GM
KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU
TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL
PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD
TG

APPLICATION INFO.: WO 2002-US1952 A 20020118
PRIORITY INFO.: US 2001-60/262,987 20010118
US 2002-60/262,987 20020117

ABEN Numerous diseases and disorders are caused or exacerbated by the formation of crystalline aggregates of a biomolecule that is normally in solution. Such diseases and disorders include cataracts, sickle cell anemia, atherosclerosis, kidney stones, gallstones, gout, and Alzheimer's disease. The present invention provides methods to identify compounds that can inhibit the adverse formation of crystalline aggregates, including fibrils, of a target biomolecule. These methods include the screening of large combinatorial libraries. The identified compounds are tested for their therapeutic utility in treating medical conditions caused or exacerbated by the adverse crystallization of biomolecules. Molecules that are slight modifications of the target biomolecule are found to be particularly effective in inhibiting the adverse crystallization, including fibril formation, of a target biomolecule.

ABFR De nombreuses maladies et troubles sont dus ou sont exacerbes par la formation d'agregats cristallins d'une biomolecule se trouvant normalement en solution. Ces maladies et troubles sont la cataracte, la drepanocytose, les calculs renaux, les calculs biliaires, la goutte et la maladie d'Alzheimer. Cette invention porte sur des procedes d'identification de composes qui peuvent inhiber la formation

indesirable d'agregats cristallins, tels que des fibrilles, d'une biomolecule cible. Ces procedes consistent a cribler de grandes bibliotheques combinatoires. Puis on teste les composees identifiees en vue de determiner leur utilite dans le traitement d'etats pathologiques dus ou exacerbes par la cristallisation indesirable de biomolecules. Les molecules qui sont de legeres modifications de la biomolecule cible s'averent etre particulierement efficaces dans l'inhibition de la cristallisation indesirable, telle que la formation de fibrilles, d'une biomolecule cible.

L12 ANSWER 15 OF 46 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2002048190 PCTFULL ED 20020709 EW 200225
 TITLE (ENGLISH): USE OF L-CARNITINE AS STABILIZING AGENT OF PROTEINS
 TITLE (FRENCH): UTILISATION DE L-CARNITINE EN TANT QU'AGENT DE
 STABILISATION DE PROTEINES
 INVENTOR(S): CALVANI, Menotti
 PATENT ASSIGNEE(S): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A., for
 all designates States except US; CALVANI, Menotti, for
 US only
 AGENT: SPADARO, Marco
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002048190	A1	20020620
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		

APPLICATION INFO.: WO 2000-IT520 A 20001215

ABEN The present invention relates to the technical field of stabilizing proteins, in particular to the therapeutic aspects of protein stabilization. L-carnitine is a useful agent for stabilizing proteins, and in a particularly favourable aspect in proteins used in the medical field. In a preferred aspect, L-carnitine is used for protecting chaperone activity, and in the medical field for preserving the activity of altered chaperone proteins. In connection with this invention L-carnitine is used for the preparation of a medicament for the treatment of diseases due to altered chaperone proteins, such as eye diseases, in particular cataract.

ABFR La presente invention concerne le domaine technique de la stabilisation de proteines, notamment les aspects therapeutiques de la stabilisation proteique. La L-carnitine est un agent d'utilite en ce qui concerne la stabilisation de proteines, particulierement en ce qui concerne les proteines utilisees dans le domaine medical. Dans un aspect preferre de l'invention, la L-carnitine est utilisee pour preserver l'activite de la chaperone, et dans le domaine medical pour preserver l'activite de proteines chaperone modifiees. Selon l'invention, la L-carnitine est utilisee pour la preparation d'un medicament servant a traiter des troubles lies aux proteines chaperone modifiees, telles que des troubles oculaires, notamment la cataracte.

L12 ANSWER 16 OF 46 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 2002040719 PCTFULL ED 20020610 EW 200221
 TITLE (ENGLISH): RETINOID PATHWAY ASSAYS, AND COMPOSITIONS THEREFROM
 TITLE (FRENCH): DOSAGES DE VOIES DU RETINOIDE, ET COMPOSITIONS
 CORRESPONDANTES
 INVENTOR(S): KAMB, Carl, Alexander; RICHARDS, Burt, Timothy;
 KARPILOW, Jon

PATENT ASSIGNEE(S): DELTAGEN PROTEOMICS, INC., for all designates States except US; KAMB, Carl, Alexander, for US only; RICHARDS, Burt, Timothy, for US only; KARPILOW, Jon, for US only

AGENT: WILLIAMS, Joseph, A., Jr.

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

DESIGNATED STATES	WO 2002040719	A2 20020523
	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR	
	CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID	
	IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD	
	MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI	
	SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE	
	LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ	
	TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT	
	SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG	

APPLICATION INFO.: WO 2001-US44039 A 20011117

PRIORITY INFO.: US 2000-60/249,468 20001117

ABEN Methods for assaying a cellular pathway, and more particularly a retinoic acid-related pathway, are disclosed. The assays of the invention utilize particular host cells with desired retinoic acid pathway elements, and results in the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

ABFR L'invention concerne des methodes de dosage d'une voie cellulaire, et plus specifiquement, d'une voie afferente a l'acide retinoique. Les dosages de cette invention utilisent des cellules hotes specifiques avec des elements de voies d'acide retinoique, ainsi que des resultats d'identification des sonde phenotypiques actives biologiquement et de fragments et cibles cellulaires, des variants et des substances mimetiques correspondantes.

L12 ANSWER 17 OF 46 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002000242 PCTFULL ED 20020814

TITLE (ENGLISH): HUMAN PAPILLOMA VIRUS TREATMENT

TITLE (FRENCH): TRAITEMENT DES INFECTIONS PAR LE PAPILLOMAVIRUS

INVENTOR(S): NEEFE, John; GOLDSTONE, Stephen; WINNETT, Mark; SIEGEL, Marvin

PATENT ASSIGNEE(S): STESSGEN BIOTECHNOLOGIES CORPORATION; NEEFE, John; GOLDSTONE, Stephen; WINNETT, Mark; SIEGEL, Marvin

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

DESIGNATED STATES	WO 2002000242	A2 20020103
	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR	
	CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL	
	IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG	
	MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ	
	TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ	
	SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH	
	CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ	
	CF CG CI CM GA GN GW ML MR NE SN TD TG	

APPLICATION INFO.: WO 2001-US20240 A 20010626

PRIORITY INFO.: US 2000-60/214,202 20000626

ABEN Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human

papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

ABFR L'invention se rapporte a une methode de traitement d'une verrue qui consiste a administrer au sujet presentant ladite verrue une composition contenant (1) une proteine de stress ou un fragment immunostimulateur d'une telle proteine, et (2) une proteine d'un papillomavirus ou un fragment antigenique dudit virus. L'invention se rapporte egalement a une methode de traitement d'une infection par papillomavirus chez un sujet infecte ou susceptible d'etre infecte par un papillomavirus d'un premier type, ledit procede consistant a administrer au sujet en question une composition contenant une proteine de stress ou un fragment antigenique d'une telle proteine et (2) une proteine d'un papillomavirus d'un second type ou un fragment antigenique d'une telle proteine, lesdits premier et second type de papillomavirus etant differents.

L12 ANSWER 18 OF 46 WPIDS (C) 2002 THOMSON DERWENT DUPLICATE 2
 ACCESSION NUMBER: 2002-011413 [01] WPIDS
 DOC. NO. CPI: C2002-002972
 TITLE: Improving stability and/or solubility of proteins expressed in vivo or in vitro.
 DERWENT CLASS: B04 D16
 INVENTOR(S): SANDERS, M C
 PATENT ASSIGNEE(S): (EXPR-N) EXPRESSIVE CONSTRUCTS INC; (SAND-I) SANDERS M C
 COUNTRY COUNT: 95
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001083804	A2	20011108	(200201)*	EN	23
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001061242	A	20011112	(200222)		
US 2002142384	A1	20021003	(200267)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001083804	A2	WO 2001-US14692	20010503
AU 2001061242	A	AU 2001-61242	20010503
US 2002142384	A1 Provisional	US 2000-201407P	20000503
		US 2001-848780	20010503

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001061242	A Based on	WO 200183804

PRIORITY APPLN. INFO: US 2000-201407P 20000503; US 2001-848780 20010503

AN 2002-011413 [01] WPIDS

AB WO 200183804 A UPAB: 20020105

NOVELTY - Methods for improving protein stability and/or solubility, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the

following:

(1) a method (I) for producing a **soluble** and active recombinant protein comprising:

- (a) inserting the p26 betas-core domain into a vector;
- (b) inserting the insoluble protein domain into the vector directly after the p26 domain;
- (c) inserting the vector into bacterial cells;
- (d) growing the bacteria in a culture to an optical density (OD) of 0.8-1.0; and
- (e) inducing the culture with IPTG;

(2) a method (II) for preventing unwanted **proteolysis** of a recombinant protein comprising:

- (A) inserting bovine **alpha-crystallin** into a vector;
- (B) inserting the protein of interest into a vector; and
- (C) steps (c) to (e) from (I);

(3) a method for purifying native bovine **alpha-crystallin** protein comprising:

- (a) homogenizing bovine eye lenses in a buffer;
- (b) binding **alpha-crystallin** protein to a Q column;
- (c) eluting the **alpha-crystallin** with a high salt; and
- (d) separating the protein in 100 mM Glycine pH 2.5 on a Macroprep (RTM) column;

(4) a method of purifying recombinant **alpha-crystallin** type HIS-tagged proteins comprising:

- (a) inserting the **alpha-crystallin** protein domain into a vector with the hexa-his tag;
- (b) inserting the vector into bacterial cells and growing/inducing the cells;
- (c) lysing the cells and centrifuging out cell debris; and
- (d) purifying the **alpha-crystallin** protein using an Ni-NTA column; and

(5) a method (V) for protecting a protein from **proteolysis** during purification, comprising:

- (A) coupling purified bovine **alpha-crystallin** protein to a chromatography resin (CNBr-activated Sepharose (RTM) 4B or NHS-activated Sepharose 4B);
- (B) rinsing and blocking the resin with BSA; and
- (C) using the resin to purify the protein of choice.

USE - The methods are used to improve protein stability, folding and/or solubility when produced either in vivo or in vitro.

Dwg.0/7

L12 ANSWER 19 OF 46 USPATFULL

ACCESSION NUMBER: 2001:220852 USPATFULL
TITLE: Chimeric DNA-binding proteins
INVENTOR(S): Pomerantz, Joel L., Cambridge, MA, United States
Sharp, Phillip A., Newton, MA, United States
Pabo, Carl O., Newton, MA, United States
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326166	B1	20011204
	WO 9620951		19960711
APPLICATION INFO.:	US 1998-973131		19980316 (8)
	WO 1995-US16982		19951229
			19980316 PCT 371 date
			19980316 PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Martinell, James		

LEGAL REPRESENTATIVE: Vincent, Matthew P.Ropes & Gray, LLP
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2890

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 20 OF 46 USPATFULL

ACCESSION NUMBER: 2001:202601 USPATFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald, Woodside, CA, United States
Schreiber, Stuart, Boston, MA, United States
Spencer, David, Houston, TX, United States
Wandless, Thomas, Palo Alto, CA, United States
Belshaw, Peter, Somerville, MA, United States
Ho, Steffan N, San Diego, CA, United States

PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316418	B1	20011113
APPLICATION INFO.:	US 1999-302629		19990430 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-87811, filed on 29 May 1998, now patented, Pat. No. US 6054436 Continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 179143 And Ser. No. US 302629 Continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned Continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Schwartzman, Robert A.

LEGAL REPRESENTATIVE: Vincent, Matthew P.Ropes & Gray

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 35 Drawing Figure(s); 34 Drawing Page(s)

LINE COUNT: 4291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 21 OF 46 USPATFULL

ACCESSION NUMBER: 2001:185087 USPATFULL

TITLE: Heterologous transcription factors

INVENTOR(S): Gilman, Michael Z., Newton, MA, United States
 Natesan, Sridaran, Chestnut Hill, MA, United States
 PATENT ASSIGNEE(S): ARIAD Gene Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6306649	B1	20011023
APPLICATION INFO.:	US 1996-672213		19960627 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-553P	19950627 (60)
	US 1995-19614P	19951229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Martin, Jill D.	
LEGAL REPRESENTATIVE:	Berstein, David L.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	2484	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials useful for practicing the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 22 OF 46 USPATFULL

ACCESSION NUMBER: 2001:86035 USPATFULL
 TITLE: Early detection of mycobacterial disease
 INVENTOR(S): Laal, Suman, Croton-on-Hudson, NY, United States
 Zolla-Pazner, Susan, New York, NY, United States
 Belisle, John T., Fort Collins, CO, United States
 PATENT ASSIGNEE(S): New York Univ. Medical Center, New York, NY, United States (U.S. corporation)
 Colorado State University, Ft. Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6245331	B1	20010612
APPLICATION INFO.:	US 1997-1984		19971231 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-34003P	19970102 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Swartz, Rodney P.	
LEGAL REPRESENTATIVE:	Venable, Livnat, Shmuel	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	51 Drawing Figure(s); 32 Drawing Page(s)	
LINE COUNT:	4630	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mt) have been identified as "early" Mt antigens on the basis early antibodies present in subjects infected with Mt prior to the development of detectable clinical disease. These early Mt antigens, in particular an 88 kDa secreted protein having a pI of about 5.2 present in Mt lipoarabinomannan-free culture filtrate, a protein characterized

as Mt antigen 85C; a protein characterized as Mt antigen MPT51, a glycoprotein characterized as Mt antigen MPT32; and a 49 kDa protein having a pI of about 5.1, are useful in immunoassay methods for early, rapid detection of TB in a subject. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mt antigen, an early Mt antibody, and immune complexes thereof. For the first time, a surrogate marker is available for inexpensive screening of individuals at heightened risk for developing TB, in particular HIV-1 infected subjects and other immunocompromised individuals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 23 OF 46 USPATFULL

ACCESSION NUMBER: 2001:18213 USPATFULL
 TITLE: Synthetic transcriptional modulators and uses thereof
 INVENTOR(S): Verdine, Gregory L., Lexington, MA, United States
 Nyanguile, Origene, Gaithersburg, MD, United States
 PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183965	B1	20010206
APPLICATION INFO.:	US 1998-208057		19981209 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot, LLP, Clauss, Isabelle M., Vincent, Matthew P.		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	3213		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 24 OF 46 USPATFULL

ACCESSION NUMBER: 2001:4472 USPATFULL
 TITLE: P53-regulated genes
 INVENTOR(S): Levine, Arnold L., Princeton, NJ, United States
 Murphy, Maureen Elizabeth, Blue Bell, PA, United States
 Mack, David H., Menlo Park, CA, United States
 Gish, Kurt Carlyle, Sunnyvale, CA, United States
 Tom, Edward Yat Wah, Sacramento, CA, United States
 PATENT ASSIGNEE(S): Affymetrix, Inc., United States (U.S. corporation)
 Princeton University, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6171798	B1	20010109
APPLICATION INFO.:	US 1999-442039		19991117 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-49025, filed on 27 Mar 1998, now patented, Pat. No. US 6020135		
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		

ASSISTANT EXAMINER: Lishibuya, Mark
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 20 Drawing Page(s)
LINE COUNT: 958

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Many genes are identified as being p53-regulated which were not heretofore known to be p53-regulated. This includes both genes whose expression is induced and genes whose expression is repressed by the expression of wild-type p53. Monitoring expression of these genes is used to provide indications of p53 status in a cell. Such monitoring can also be used to screen for useful anti-cancer therapeutics, as well as for substances which are carcinogenic. Defects in p53 can be bypassed by supplying p53 induced genes to cells. Defects in p53 can also be bypassed by supplying antisense constructs to p53-repressed genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 25 OF 46 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001012659 PCTFULL ED 20020828
TITLE (ENGLISH): HUMAN DNA SEQUENCES
TITLE (FRENCH): SEQUENCE D'ADN HUMAIN
INVENTOR(S): WIEMANN, Stefan
PATENT ASSIGNEE(S): GERMAN HUMAN GENOME PROJECT; WIEMANN, Stefan
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001012659	A2	20010222
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-IB1496	A	20000818
PRIORITY INFO.:	US 1999-60/149,499		19990818
	US 1999-60/156,503		19990928

ABEN Novel human cDNA sequence of a clones, the encoded protein sequence of a clones, antibodies and variants thereof, are provided. The disclosed sequence of a clones find application in a number of ways, including use in profiling assays. In this regard, various assemblages of nucleic acids or proteins are provided that are useful in providing large arrays of human material for implementing large-scale screening strategies. The disclosed sequence of a clones may also be used in formulating medicaments, treating various disorders and in certain diagnostic applications.

ABFR

L12 ANSWER 26 OF 46 USPATFULL
ACCESSION NUMBER: 2000:160780 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., 91 Outlook Dr., Lexington, MA, United States 02173
Nyanguile, Origene, 2517 Baltimore Rd. #4, Rockville, MD, United States 20853

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153383		20001128
APPLICATION INFO.:	US 1997-987912		19971209 (8)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartzman, Robert A.
LEGAL REPRESENTATIVE: Foley, Hoag & Eliot LLP, Vincent, Matthew P., Clauss, Isabelle M.
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 27 OF 46 USPATFULL

ACCESSION NUMBER: 2000:50686 USPATFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland S. Stanford Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054436		20000425
APPLICATION INFO.:	US 1998-87811		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Hausdorff, Sharon F., Clauss, Isabelle M.

NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 5061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 28 OF 46 USPATFULL

ACCESSION NUMBER: 2000:31403 USPATFULL
TITLE: Compositions containing nucleic acids and ligands for
therapeutic treatment
INVENTOR(S): Baird, J. Andrew, San Diego, CA, United States
Chandler, Lois Ann, Encinitas, CA, United States
Sosnowski, Barbara A., Coronado, CA, United States
PATENT ASSIGNEE(S): Selective Genetics, Inc., La Jolla, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6037329		20000314
APPLICATION INFO.:	US 1996-718904		19960924 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-213447, filed on 15 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-297961, filed on 29 Aug 1994, now abandoned And Ser. No. US 1994-305771, filed on 13 Sep 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Priebe, Scott D.		
ASSISTANT EXAMINER:	Nguyen, Dave Trong		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	34 Drawing Figure(s); 25 Drawing Page(s)		
LINE COUNT:	7163		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 29 OF 46 USPATFULL

ACCESSION NUMBER: 2000:12598 USPATFULL
TITLE: P53-regulated genes
INVENTOR(S): Levine, Arnold J., Princeton, NJ, United States
Murphy, Maureen Elizabeth, Blue Bell, PA, United States
Mack, David H., Menlo Park, CA, United States
Gish, Kurt Carlyle, Sunnyvale, CA, United States
Tom, Edward Yat Wah, Sacramento, CA, United States
PATENT ASSIGNEE(S): Affymetrix, Inc., United States (U.S. corporation)
Princeton University, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020135		20000201
APPLICATION INFO.:	US 1998-49025		19980327 (9)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: Granted
PRIMARY EXAMINER: LeGuyader, John L.
ASSISTANT EXAMINER: Shibuya, Mark L.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 20 Drawing Page(s)
LINE COUNT: 1239

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Many genes are identified as being p53-regulated which were not heretofore known to be p53-regulated. This includes both genes whose expression is induced and genes whose expression is repressed by the expression of wild-type p53. Monitoring expression of these genes is used to provide indications of p53 status in a cell. Such monitoring can also be used to screen for useful anti-cancer therapeutics, as well as for substances which are carcinogenic. Defects in p53 can be bypassed by supplying p53 induced genes to cells. Defects in p53 can also be bypassed by supplying antisense constructs to p53-repressed genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 30 OF 46 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000061621 PCTFULL ED 20020515
TITLE (ENGLISH): FLEA HEAD, NERVE CORD, HINDGUT AND MALPIGHIAN TUBULE NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF
TITLE (FRENCH): MOLECULES D'ACIDES NUCLEIQUES ET PROTEINES ISSUES DE LA TETE, DE LA MOELLE EPINIERE, DE L'INTESTIN POSTERIEUR ET DU TUBE DE MALPIGHI DE PUCES ET UTILISATIONS CORRESPONDANTES
INVENTOR(S): BRANDT, Kevin, S.; GAINES, Patrick, J.; STINCHCOMB, Dan, T.; WISNEWSKI, Nancy
PATENT ASSIGNEE(S): HESKA CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000061621	A2	20001019
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US9437	A	20000407
PRIORITY INFO.:	US 1999-60/128,704		19990409

ABEN The present invention relates to flea head, nerve cord, hindgut and malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from

flea infestation. Also included in the present invention is the use of flea head, nerve cord, hindgut and Malpighian tubule proteins to derive inhibitory compounds.

ABFR La presente invention se rapporte a des proteines issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de Malpighi de puces, a des molecules d'acides nucleiques issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de Malpighi de puces, et notamment des molecules d'acides nucleiques qui codent pour ces proteines de la tete, la moelle epiniere, l'intestin posterieur et le tube de Malpighi de puces, ainsi qu'a des anticorps diriges contre l'activite des proteines de la tete, la moelle epiniere, l'intestin posterieur et le tube de Malpighi de puces. La presente invention se rapporte egalement a des procedes permettant de produire ces proteines, molecules d'acides nucleiques, anticorps et composees inhibiteurs. Elle se rapporte egalement a des compositions therapeutiques comportant des proteines, des molecules d'acides nucleiques ou des composees protecteurs derives des proteines decrites ci-dessus ainsi qu'a l'utilisation de ces compositions therapeutiques pour proteger des animaux contre l'infestation par des puces. La presente invention se rapporte en outre a l'utilisation de proteines issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de Malpighi de puces pour produire des composees inhibiteurs.

L12 ANSWER 31 OF 46 USPATFULL

ACCESSION NUMBER: 1999:155696 USPATFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of the Leland S. Stanford, Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994313		19991130
APPLICATION INFO.:	US 1995-483898		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned And Ser. No. US 1994-179143, filed on 17 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 196043 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		

ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Berstein, David L., Hausdorff, Sharon F., Vincent,
Matthew P.

NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 4791

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 32 OF 46 USPATFULL

ACCESSION NUMBER: 1999:132249 USPATFULL
TITLE: Healthy foods and cosmetics
INVENTOR(S): Yamaguchi, Fumio, Noda, Japan
Saito, Makoto, Noda, Japan
Ishikawa, Hiroharu, Noda, Japan
Kataoka, Shigehiro, Noda, Japan
Ariga, Toshiaki, Noda, Japan
PATENT ASSIGNEE(S): Kikkoman Corporation, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972357		19991026
APPLICATION INFO.:	US 1997-975713		19971121 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-353869	19961219
	JP 1997-199119	19970710
	JP 1997-199120	19970710

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Clardy, S. Mark
ASSISTANT EXAMINER: Williamson, Michael A.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to healthy foods and cosmetics. More particularly, it relates to healthy foods and cosmetics containing a polyisoprenylated benzophenone derivatives as effective ingredients and having a variety of functions for maintaining health such as anti-ulcer activity, the Maillard reaction inhibiting activity, anti-oxidation activity, reactive oxygen species scavenging activity, and anti-tumor promotion activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 33 OF 46 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999030164 PCTFULL ED 20020515
TITLE (ENGLISH): METHOD TO IDENTIFY TRANSCRIPTIONAL MODULATORS
TITLE (FRENCH): PROCEDE D'IDENTIFICATION DE MODULATEURS DE
TRANSCRIPTION
INVENTOR(S): VERDINE, Gregory, L.; NYANGUILE, Origene
PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9930164	A1	19990617
DESIGNATED STATES	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1998-US26101	A	19981209
PRIORITY INFO.:	US 1997-08/987,912		19971209
ABEN	Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.		
ABFR	L'invention porte sur de nouveaux modulateurs de transcription de synthese presentant au moins un ligand selectionne lie a au moins une portion modulant la transcription. Lesdits modulateurs, qui peuvent comporter un ligand lie a un fragment chimique, peuvent servir a reguler selectivement l'expression de genes et a identifier certains composants du mecanisme de transcription.		

L12 ANSWER 34 OF 46 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1999007860 PCTFULL ED 20020515

TITLE (ENGLISH): IMMUNE RESPONSES AGAINST HPV ANTIGENS ELICITED BY COMPOSITIONS COMPRISING AN HPV ANTIGEN AND A STRESS PROTEIN OR AN EXPRESSION VECTOR CAPABLE OF EXPRESSION OF THESE PROTEINS

TITLE (FRENCH): REPONSES IMMUNITAIRES CONTRE LES ANTIGENES DU VPH ET DECLENCHEES PAR DES COMPOSITIONS COMPRENANT UN ANTIGENE DU VPH, ET PROTEINE DU STRESS OU VECTEUR D'EXPRESSION CAPABLE D'EXPRIMER CES PROTEINES

INVENTOR(S): MIZZEN, Lee; CHU, Randall

PATENT ASSIGNEE(S): STRESSGEN BIOTECHNOLOGIES CORPORATION; MIZZEN, Lee; CHU, Randall

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9907860	A1	19990218
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-CA246	A	19980320
PRIORITY INFO.:	US 1997-60/054,835		19970805
ABEN	The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the		

stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject *in vivo*, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

ABFR La presente invention concerne des compositions permettant d'induire une reponse immunitaire, de preference une reponse immunitaire cellulaire de type II, et plus particulierement a mediation cellulaire, contre les antigenes du Virus des Papillomes Humains (VPH) que montre le VPH, ou que montrent des cellules infectees des tumeurs du col de l'uterus et d'autres tumeurs. Une realisation de l'invention porte sur des compositions comprenant une proteine antigene du VPH jointe a une proteine du stress (Hsp). L'antigene du VPH peut etre joint a une proteine du stress par conjugaison chimique ou par non-covalence en utilisant des groupes fonctionnels de liaison. Mais l'antigene du VPH peut egalement etre joint dans une proteine hybride contenant d'une part l'antigene du VPH, et d'autre part des sequences de proteine du stress. Une autre realisation porte sur des compositions comprenant un vecteur d'expression incluant, sous forme exprimable, des sequences codant pour l'antigene du VPH et des sequences codant pour la proteine du stress. Le vecteur d'expression peut etre introduit dans les cellules d'un sujet. Mais il peut egalement servir a la transduction de cellules du sujet *in vivo*, ce qui aboutit a l'expression d'une proteine hybride proteine du stress - antigene du VPH qui doit normalement stimuler la reponse immunitaire du sujet a l'antigene du VPH. L'invention concerne egalement, non seulement des compositions comprenant une proteine du stress liee a un antigene du VPH et un autre composant pharmacologiquement acceptable, mais aussi des hybrides et des conjugues proteine du stress - antigene du VPH, et enfin des vecteurs d'expression codant pour et capable de diriger l'expression dans les cellules d'un sujet dans le cas d'une proteine hybride comprenant une proteine du stress et une sequence antigene du VPH. L'invention concerne enfin l'utilisation de ces compositions pour induire les reponses immunitaires

contre le VPH et des cellules montrant l'antigene VPH, y compris les tumeurs liees au VPH.

L12 ANSWER 35 OF 46 USPATFULL

ACCESSION NUMBER: 1998:138709 USPATFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834266		19981110
APPLICATION INFO.:	US 1994-292597		19940818 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned And Ser. No. US 1994-179748, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned , said Ser. No. US 179143 which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Clauss, Isabelle M.Foley, Hoag & Eliot LLP		
NUMBER OF CLAIMS:	235		
EXEMPLARY CLAIM:	118		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	5299		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 36 OF 46 USPATFULL

ACCESSION NUMBER: 1998:108251 USPATFULL
TITLE: Recombinant production of proteins using 7B2 protein
INVENTOR(S): Martens, Gerardus Julianus Maria, Nijmegen, Netherlands
Chaudhuri, Bhabatosh, Munchenstein, Switzerland
Stephan, Christine, Kingersheim, France
PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804417		19980908
APPLICATION INFO.:	US 1996-709915		19960909 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-244492, filed on 2 Sep 1994, now patented, Pat. No. US 5708140		

NUMBER DATE

PRIORITY INFORMATION: NL 1991-2009 19911129
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hendricks, Keith D.
LEGAL REPRESENTATIVE: Nowak, Henry P.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention lies in the field of genetic engineering and, in particular, is concerned with the use of 7B2 as chaperone in vivo or in vitro. The invention accordingly concerns a method for producing a desired protein in vivo with the aid of recombinant cells capable of expressing 7B2 and of expressing and secreting said desired protein. Another aspect is accordingly an in vitro method for the deaggregation or prevention of aggregation of protein by treating the protein with 7B2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 37 OF 46 USPATFULL

ACCESSION NUMBER: 1998:85942 USPATFULL
TITLE: Microparticles for delivery of nucleic acid
INVENTOR(S): Hedley, Mary Lynne, Belmont, MA, United States
Curley, Joanne M., San Mateo, CA, United States
Langer, Robert S., Newton, MA, United States
PATENT ASSIGNEE(S): Pangaea Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5783567		19980721
APPLICATION INFO.:	US 1997-787547		19970122 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Degen, Nancy		
ASSISTANT EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	1732		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a preparation of microparticles made up of a polymeric matrix and a nucleic acid expression vector. The polymeric matrix includes one or more synthetic polymers having a solubility in water of less than about 1 mg/l. At least 90% of the microparticles have a diameter less than about 100 microns. The nucleic acid is either RNA, at least 50% of which is in the form of closed circles, or circular DNA plasmid molecules, at least 50% of which are supercoiled.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 38 OF 46 USPATFULL

ACCESSION NUMBER: 1998:4738 USPATFULL
TITLE: Production of proteins using 7B2 protein
INVENTOR(S): Martens, Gerardus Julianus Maria, Nijmegen, Netherlands
Chaudhuri, Bhabatosh, Munchenstein, Switzerland
Stephan, Christine, Kingersheim, France
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Summit, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 5708140	19980113	
	WO 9311248	19930610	
APPLICATION INFO.:	US 1994-244492	19940902	(8)
	WO 1992-EP2740	19921127	
		19940902	PCT 371 date
		19940902	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	NL 1991-2009	19911129
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hendricks, Keith D.	
LEGAL REPRESENTATIVE:	Nowak, Henry P., Spruill, W. Murray	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1533	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention lies in the field of genetic engineering and, in particular, is concerned with the use of 7B2 as chaperone in vivo or in vitro. The invention accordingly concerns a method for producing a desired protein in vivo with the aid of recombinant cells capable of expressing 7B2 and of expressing and secreting said desired protein. Another aspect is accordingly an in vitro method for the deaggregation or prevention of aggregation of protein by treating the protein with 7B2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 39 OF 46 USPATFULL

ACCESSION NUMBER: 97:71170 USPATFULL
 TITLE: DNA encoding macrophage migration inhibition factor from ocular lens
 INVENTOR(S): Wistow, Graeme John, Silver Spring, MD, United States
 PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656737		19970812
APPLICATION INFO.:	US 1994-202486		19940228 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-691191, filed on 26 Apr 1991, now patented, Pat. No. US 5328990		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Walsh, Stephen		
ASSISTANT EXAMINER:	Spector, Lorraine		
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	470		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Macrophage Migration Inhibition Factor (MIF) can be obtained from ocular lens of various birds and mammals. The amino acid sequences of lens MIF from mice, chickens and humans has been determined and the corresponding cDNA has been cloned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 40 OF 46 USPATFULL

ACCESSION NUMBER: 95:43178 USPATFULL
 TITLE: Cholera toxin gene regulated by tissue-specific

INVENTOR(S): promoters
 Burton, Frank H., San Diego, CA, United States
 Sutcliffe, J. Gregor, Cardiff, CA, United States
 PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5416017		19950516
APPLICATION INFO.:	US 1993-37013		19930325 (8)
DISCLAIMER DATE:	20100629		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-528852, filed on 18 May 1990, now patented, Pat. No. US 5233610		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartz, Richard A.		
ASSISTANT EXAMINER:	Carter, Philip W.		
LEGAL REPRESENTATIVE:	Logan, April C.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2429		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention contemplates a method of physiologic engineering by genetically altering second messenger levels in cells. This method allows the hyperactivation or inhibition of cell function within cells, tissues and animals by introducing a foreign gene that alters a second messenger system. The use of physiologically engineered animals as systems for determining the effectiveness of therapeutic compositions is also contemplated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 41 OF 46 USPATFULL

ACCESSION NUMBER: 95:7820 USPATFULL
 TITLE: Ubiquitin carrier enzyme E2-F1, purification, production, and use
 INVENTOR(S): Ciechanover, Aaron J., Haifa, Israel
 Blumenfeld, Nava, Haifa, Israel
 Gonen, Hedva, Haifa, Israel
 PATENT ASSIGNEE(S): Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5384255		19950124
APPLICATION INFO.:	US 1993-80073		19930621 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Prouty, Rebecca		
LEGAL REPRESENTATIVE:	Sterne, Kessler Goldstein & Fox		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2266		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for isolating and purifying novel species of E2 ubiquitin-carrier protein, designated E2-F1, is disclosed. A method for preparing enzymatically active fragments of E2-F1 enzyme is also disclosed. The use of purified E2-F1 to produce antibodies is also disclosed. The use of such E2-F1-specific antibodies to detect the presence of E2-F1 in a biological sample, and to inhibit protein **degradation** are also disclosed. Recombinant DNA molecules which code for E2-F1, and recombinant hosts and vectors which contain E2-F1

coding sequences are also disclosed. The use of such recombinant hosts and vectors to produce E2-F1 protein is also disclosed. The use of purified E2-F1 to identify and to isolate E3 enzyme is also disclosed. Methods for screening substances for the ability to inhibit E2-F1 enzyme activity are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 42 OF 46 USPATFULL

ACCESSION NUMBER: 94:60239 USPATFULL
TITLE: Isolation of macrophage migration inhibition factor from ocular lens
INVENTOR(S): Wistow, Graeme J., Silver Spring, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5328990		19940712
APPLICATION INFO.:	US 1991-691191		19910426 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hill, Jr., Robert J.		
ASSISTANT EXAMINER:	Spector, L.		
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
LINE COUNT:	431		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Macrophage Migration Inhibition Factor (MIF) can be obtained from ocular lens of various birds and mammals. The amino acid sequences of lens MIF from mice, chickens and humans has been determined and the corresponding cDNA has been cloned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 43 OF 46 USPATFULL

ACCESSION NUMBER: 94:57739 USPATFULL
TITLE: Process for synthesizing human H2-prorelin, human H2-relin and fusion proteins thereof
INVENTOR(S): Hudson, Peter J., Bulleen, Australia
Niall, Hugh D., Elwood, Australia
Tregear, Geoffrey W., Hawthorn, Australia
PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology and Medicine, Victoria, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5326694		19940705
APPLICATION INFO.:	US 1992-871318		19920420 (7)
DISCLAIMER DATE:	20050719		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-665129, filed on 6 Mar 1991, now patented, Pat. No. US 5179195 which is a division of Ser. No. US 1987-21885, filed on 4 Mar 1987, now patented, Pat. No. US 5023321 which is a division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented, Pat. No. US 4758516		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hill, Jr., Robert J.	

ASSISTANT EXAMINER: Teng, Sally P.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1009

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer vectors for the expression of human preprorelaxin; sub-units thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 44 OF 46 USPATFULL

ACCESSION NUMBER: 93:3675 USPATFULL
TITLE: Human relaxin polypeptides
INVENTOR(S): Hudson, Peter J., Victoria, Australia
Niall, Hugh D., Victoria, Australia
Tregear, Geoffrey W., Victoria, Australia
PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology and Medicine, Melbourne, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5179195		19930112
APPLICATION INFO.:	US 1991-665129		19910306 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1987-21885, filed on 4 Mar 1987, now patented, Pat. No. US 5023321 which is a division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented, Pat. No. US 4758516		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lacey, David L.	
ASSISTANT EXAMINER:	Ossanna, Nina	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	992	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer vectors for the expression of human preprorelaxin; sub-units thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 45 OF 46 USPATFULL

ACCESSION NUMBER: 91:46779 USPATFULL
TITLE: Molecular cloning and characterization of a further gene sequence coding for human relaxin
INVENTOR(S): Hudson, Peter J., Bulleen, Australia
Niall, Hugh D., Elwood, Australia
Tregear, Geoffrey W., Hawthorn, Australia
PATENT ASSIGNEE(S): Howard Florey Institute of Experimental Physiology & Medicine, Victoria, Australia (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 5023321	19910611
APPLICATION INFO.:	US 1987-21885	19870304 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented, Pat. No. US 4758516	

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Moskowitz, Margaret	
ASSISTANT EXAMINER:	Ossanna, Nina	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	2	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	963	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer vectors for the expression of human preprorelaxin; sub-units thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 46 OF 46 USPATFULL

ACCESSION NUMBER:	88:45600 USPATFULL
TITLE:	Molecular cloning and characterization of a further gene sequence coding for human relaxin
INVENTOR(S):	Hudson, Peter J., Bulleen, Australia Niall, Hugh D., Elwood, Australia Tregear, Geoffrey W., Hawthorn, Australia
PATENT ASSIGNEE(S):	Howard Florey Institute of Experimental Physiology and Medicine, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4758516		19880719
APPLICATION INFO.:	US 1983-560790		19831213 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1982-7247	19821213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wiseman, Thomas G.	
ASSISTANT EXAMINER:	Huleatt, Jayme A.	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak, and Seas	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	1017	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes and DNA transfer vectors for the expression of human preprorelaxin; sub-units thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

